JPH10506624A - ピロロ〔2,3−d〕ピリミジン及びその使用 - Google Patents
ピロロ〔2,3−d〕ピリミジン及びその使用Info
- Publication number
- JPH10506624A JPH10506624A JP8511312A JP51131296A JPH10506624A JP H10506624 A JPH10506624 A JP H10506624A JP 8511312 A JP8511312 A JP 8511312A JP 51131296 A JP51131296 A JP 51131296A JP H10506624 A JPH10506624 A JP H10506624A
- Authority
- JP
- Japan
- Prior art keywords
- lower alkyl
- alkoxy
- alkyl
- alkylamino
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- JJTNLWSCFYERCK-UHFFFAOYSA-N 7h-pyrrolo[2,3-d]pyrimidine Chemical compound N1=CN=C2NC=CC2=C1 JJTNLWSCFYERCK-UHFFFAOYSA-N 0.000 title description 3
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims abstract description 13
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims abstract description 13
- 239000003814 drug Substances 0.000 claims abstract description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 311
- 125000003545 alkoxy group Chemical group 0.000 claims description 241
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 181
- -1 (piperidini Chemical group 0.000 claims description 173
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 128
- 125000003282 alkyl amino group Chemical group 0.000 claims description 109
- 150000001875 compounds Chemical class 0.000 claims description 103
- 150000003839 salts Chemical class 0.000 claims description 91
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 82
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 82
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims description 78
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims description 74
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 68
- 125000005236 alkanoylamino group Chemical group 0.000 claims description 60
- 125000004423 acyloxy group Chemical group 0.000 claims description 57
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 57
- 125000001425 triazolyl group Chemical group 0.000 claims description 53
- 125000004193 piperazinyl group Chemical group 0.000 claims description 50
- 125000004076 pyridyl group Chemical group 0.000 claims description 50
- 125000002883 imidazolyl group Chemical group 0.000 claims description 49
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 48
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 47
- 125000002757 morpholinyl group Chemical group 0.000 claims description 46
- 125000003386 piperidinyl group Chemical group 0.000 claims description 40
- 238000000034 method Methods 0.000 claims description 37
- 229910052757 nitrogen Inorganic materials 0.000 claims description 37
- 229910052739 hydrogen Inorganic materials 0.000 claims description 35
- 239000001257 hydrogen Substances 0.000 claims description 35
- 229910052736 halogen Inorganic materials 0.000 claims description 34
- 150000002367 halogens Chemical class 0.000 claims description 29
- 125000004414 alkyl thio group Chemical group 0.000 claims description 24
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 23
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 20
- 125000004457 alkyl amino carbonyl group Chemical group 0.000 claims description 18
- 125000001424 substituent group Chemical group 0.000 claims description 18
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 12
- 150000002431 hydrogen Chemical class 0.000 claims description 12
- 238000002360 preparation method Methods 0.000 claims description 12
- 125000003118 aryl group Chemical group 0.000 claims description 11
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 11
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 11
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 claims description 10
- 125000006306 4-iodophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1I 0.000 claims description 10
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 10
- 230000000694 effects Effects 0.000 claims description 10
- 230000015572 biosynthetic process Effects 0.000 claims description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 9
- SCVJRXQHFJXZFZ-KVQBGUIXSA-N 2-amino-9-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purine-6-thione Chemical compound C1=2NC(N)=NC(=S)C=2N=CN1[C@H]1C[C@H](O)[C@@H](CO)O1 SCVJRXQHFJXZFZ-KVQBGUIXSA-N 0.000 claims description 8
- 241001024304 Mino Species 0.000 claims description 7
- 239000003153 chemical reaction reagent Substances 0.000 claims description 7
- 238000007363 ring formation reaction Methods 0.000 claims description 7
- 238000003786 synthesis reaction Methods 0.000 claims description 7
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims description 6
- 241001465754 Metazoa Species 0.000 claims description 6
- 125000005037 alkyl phenyl group Chemical group 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 6
- HKIOYBQGHSTUDB-UHFFFAOYSA-N folpet Chemical group C1=CC=C2C(=O)N(SC(Cl)(Cl)Cl)C(=O)C2=C1 HKIOYBQGHSTUDB-UHFFFAOYSA-N 0.000 claims description 6
- APVPOHHVBBYQAV-UHFFFAOYSA-N n-(4-aminophenyl)sulfonyloctadecanamide Chemical compound CCCCCCCCCCCCCCCCCC(=O)NS(=O)(=O)C1=CC=C(N)C=C1 APVPOHHVBBYQAV-UHFFFAOYSA-N 0.000 claims description 6
- 125000005530 alkylenedioxy group Chemical group 0.000 claims description 5
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 claims description 5
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 claims description 5
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 claims description 4
- 230000005764 inhibitory process Effects 0.000 claims description 4
- 125000000020 sulfo group Chemical group O=S(=O)([*])O[H] 0.000 claims description 4
- MHCVCKDNQYMGEX-UHFFFAOYSA-N 1,1'-biphenyl;phenoxybenzene Chemical group C1=CC=CC=C1C1=CC=CC=C1.C=1C=CC=CC=1OC1=CC=CC=C1 MHCVCKDNQYMGEX-UHFFFAOYSA-N 0.000 claims description 3
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 3
- WCDWBPCFGJXFJZ-UHFFFAOYSA-N etanidazole Chemical group OCCNC(=O)CN1C=CN=C1[N+]([O-])=O WCDWBPCFGJXFJZ-UHFFFAOYSA-N 0.000 claims description 3
- 230000001225 therapeutic effect Effects 0.000 claims description 3
- 230000004913 activation Effects 0.000 claims description 2
- 125000003368 amide group Chemical group 0.000 claims description 2
- 239000000969 carrier Substances 0.000 claims description 2
- 125000000590 4-methylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 3
- GYPCWHHQAVLMKO-XXKQIVDLSA-N (7s,9s)-7-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-[(e)-n-[(1-hydroxy-2,2,6,6-tetramethylpiperidin-4-ylidene)amino]-c-methylcarbonimidoyl]-4-methoxy-8,10-dihydro-7h-tetracene-5,12-dione;hydrochloride Chemical group Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(\C)=N\N=C1CC(C)(C)N(O)C(C)(C)C1)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 GYPCWHHQAVLMKO-XXKQIVDLSA-N 0.000 claims 1
- 241000009298 Trigla lyra Species 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 102000001332 SRC Human genes 0.000 abstract description 2
- 108060006706 SRC Proteins 0.000 abstract description 2
- 229940079593 drug Drugs 0.000 abstract description 2
- 239000003112 inhibitor Substances 0.000 abstract 1
- 150000004943 pyrrolo[2,3-d]pyrimidines Chemical class 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 240
- 239000000203 mixture Substances 0.000 description 143
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical group CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 127
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 93
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 87
- 235000019441 ethanol Nutrition 0.000 description 65
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 60
- 239000011734 sodium Substances 0.000 description 56
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 48
- 239000000047 product Substances 0.000 description 48
- 238000002844 melting Methods 0.000 description 45
- 230000008018 melting Effects 0.000 description 45
- 239000013078 crystal Substances 0.000 description 35
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 34
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 33
- 239000000741 silica gel Substances 0.000 description 33
- 229910002027 silica gel Inorganic materials 0.000 description 33
- 238000001914 filtration Methods 0.000 description 31
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 30
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 28
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 27
- 239000012074 organic phase Substances 0.000 description 27
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 26
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 24
- 239000008346 aqueous phase Substances 0.000 description 24
- 238000004587 chromatography analysis Methods 0.000 description 24
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 23
- 239000004480 active ingredient Substances 0.000 description 23
- 238000001816 cooling Methods 0.000 description 23
- 229910052708 sodium Inorganic materials 0.000 description 23
- 239000012141 concentrate Substances 0.000 description 22
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 21
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 20
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 18
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 18
- 239000003208 petroleum Substances 0.000 description 18
- 229910021529 ammonia Inorganic materials 0.000 description 17
- 238000001035 drying Methods 0.000 description 17
- 239000012452 mother liquor Substances 0.000 description 17
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 16
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 16
- CUONGYYJJVDODC-UHFFFAOYSA-N malononitrile Chemical compound N#CCC#N CUONGYYJJVDODC-UHFFFAOYSA-N 0.000 description 15
- 238000005160 1H NMR spectroscopy Methods 0.000 description 14
- 125000004207 3-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(OC([H])([H])[H])=C1[H] 0.000 description 14
- 238000000746 purification Methods 0.000 description 14
- 125000006012 2-chloroethoxy group Chemical group 0.000 description 13
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 13
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 12
- 239000002585 base Substances 0.000 description 12
- 238000006243 chemical reaction Methods 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 125000004208 3-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C([H])C(*)=C1[H] 0.000 description 11
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 11
- 239000002253 acid Substances 0.000 description 11
- 230000031709 bromination Effects 0.000 description 11
- 238000005893 bromination reaction Methods 0.000 description 11
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 11
- 229910052794 bromium Inorganic materials 0.000 description 11
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 11
- 238000003756 stirring Methods 0.000 description 11
- DXXPALPCLCHBSU-UHFFFAOYSA-N 3-(2-chloroethoxy)aniline Chemical compound NC1=CC=CC(OCCCl)=C1 DXXPALPCLCHBSU-UHFFFAOYSA-N 0.000 description 10
- 150000003973 alkyl amines Chemical class 0.000 description 10
- 239000012298 atmosphere Substances 0.000 description 10
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 10
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 10
- 229940050176 methyl chloride Drugs 0.000 description 10
- 239000003921 oil Substances 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- ODWXUNBKCRECNW-UHFFFAOYSA-M bromocopper(1+) Chemical compound Br[Cu+] ODWXUNBKCRECNW-UHFFFAOYSA-M 0.000 description 9
- 235000019198 oils Nutrition 0.000 description 9
- 238000010992 reflux Methods 0.000 description 9
- RTZZCYNQPHTPPL-UHFFFAOYSA-N 3-nitrophenol Chemical compound OC1=CC=CC([N+]([O-])=O)=C1 RTZZCYNQPHTPPL-UHFFFAOYSA-N 0.000 description 8
- KWOLFJPFCHCOCG-UHFFFAOYSA-N Acetophenone Chemical compound CC(=O)C1=CC=CC=C1 KWOLFJPFCHCOCG-UHFFFAOYSA-N 0.000 description 8
- 238000002425 crystallisation Methods 0.000 description 8
- 230000008025 crystallization Effects 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 239000007787 solid Substances 0.000 description 8
- 239000007858 starting material Substances 0.000 description 8
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 7
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 7
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 7
- 238000005574 benzylation reaction Methods 0.000 description 7
- 210000000988 bone and bone Anatomy 0.000 description 7
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 7
- 239000012299 nitrogen atmosphere Substances 0.000 description 7
- 239000002002 slurry Substances 0.000 description 7
- 239000003826 tablet Substances 0.000 description 7
- QMSVNDSDEZTYAS-UHFFFAOYSA-N 1-bromo-1-chloroethane Chemical compound CC(Cl)Br QMSVNDSDEZTYAS-UHFFFAOYSA-N 0.000 description 6
- YNCPXBIZAPNQIJ-UHFFFAOYSA-N 1h-imidazole;sodium Chemical compound [Na].C1=CNC=N1 YNCPXBIZAPNQIJ-UHFFFAOYSA-N 0.000 description 6
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 6
- LUJMEECXHPYQOF-UHFFFAOYSA-N 3-hydroxyacetophenone Chemical compound CC(=O)C1=CC=CC(O)=C1 LUJMEECXHPYQOF-UHFFFAOYSA-N 0.000 description 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 6
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 6
- JPOXNPPZZKNXOV-UHFFFAOYSA-N bromochloromethane Chemical compound ClCBr JPOXNPPZZKNXOV-UHFFFAOYSA-N 0.000 description 6
- 238000005984 hydrogenation reaction Methods 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 238000005192 partition Methods 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 239000000454 talc Substances 0.000 description 6
- 229910052623 talc Inorganic materials 0.000 description 6
- 235000012222 talc Nutrition 0.000 description 6
- 125000003396 thiol group Chemical class [H]S* 0.000 description 6
- GKASDNZWUGIAMG-UHFFFAOYSA-N triethyl orthoformate Chemical compound CCOC(OCC)OCC GKASDNZWUGIAMG-UHFFFAOYSA-N 0.000 description 6
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 5
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- 235000019253 formic acid Nutrition 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 125000001037 p-tolyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- XEAOEIVIOZUGBP-UHFFFAOYSA-N 1-(2-anilinophenyl)propan-1-one Chemical compound CCC(=O)C1=CC=CC=C1NC1=CC=CC=C1 XEAOEIVIOZUGBP-UHFFFAOYSA-N 0.000 description 4
- IBYHHJPAARCAIE-UHFFFAOYSA-N 1-bromo-2-chloroethane Chemical compound ClCCBr IBYHHJPAARCAIE-UHFFFAOYSA-N 0.000 description 4
- BQMPGKPTOHKYHS-UHFFFAOYSA-N 1h-pyrrole-2-carbonitrile Chemical compound N#CC1=CC=CN1 BQMPGKPTOHKYHS-UHFFFAOYSA-N 0.000 description 4
- RYFDHCYKRBLYCF-UHFFFAOYSA-N 3-[4-amino-7-[3-[3-(2-hydroxyethylamino)propoxy]phenyl]pyrrolo[2,3-d]pyrimidin-5-yl]phenol Chemical compound C1=2C(N)=NC=NC=2N(C=2C=C(OCCCNCCO)C=CC=2)C=C1C1=CC=CC(O)=C1 RYFDHCYKRBLYCF-UHFFFAOYSA-N 0.000 description 4
- 125000004179 3-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(Cl)=C1[H] 0.000 description 4
- TXFPEBPIARQUIG-UHFFFAOYSA-N 4'-hydroxyacetophenone Chemical compound CC(=O)C1=CC=C(O)C=C1 TXFPEBPIARQUIG-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- 229920002261 Corn starch Polymers 0.000 description 4
- 108010010803 Gelatin Proteins 0.000 description 4
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 4
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 125000003277 amino group Chemical group 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000008120 corn starch Substances 0.000 description 4
- 239000008298 dragée Substances 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 239000013067 intermediate product Substances 0.000 description 4
- 238000005342 ion exchange Methods 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 description 4
- 210000002997 osteoclast Anatomy 0.000 description 4
- LIGACIXOYTUXAW-UHFFFAOYSA-N phenacyl bromide Chemical compound BrCC(=O)C1=CC=CC=C1 LIGACIXOYTUXAW-UHFFFAOYSA-N 0.000 description 4
- 150000003230 pyrimidines Chemical class 0.000 description 4
- 125000006413 ring segment Chemical group 0.000 description 4
- 239000000377 silicon dioxide Substances 0.000 description 4
- XGVXKJKTISMIOW-ZDUSSCGKSA-N simurosertib Chemical compound N1N=CC(C=2SC=3C(=O)NC(=NC=3C=2)[C@H]2N3CCC(CC3)C2)=C1C XGVXKJKTISMIOW-ZDUSSCGKSA-N 0.000 description 4
- MAYZWDRUFKUGGP-VIFPVBQESA-N (3s)-1-[5-tert-butyl-3-[(1-methyltetrazol-5-yl)methyl]triazolo[4,5-d]pyrimidin-7-yl]pyrrolidin-3-ol Chemical compound CN1N=NN=C1CN1C2=NC(C(C)(C)C)=NC(N3C[C@@H](O)CC3)=C2N=N1 MAYZWDRUFKUGGP-VIFPVBQESA-N 0.000 description 3
- SHYRNAJCPIECFE-UHFFFAOYSA-N 1-(2-anilinophenyl)ethanone Chemical compound CC(=O)C1=CC=CC=C1NC1=CC=CC=C1 SHYRNAJCPIECFE-UHFFFAOYSA-N 0.000 description 3
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 3
- UBIUANGMGZYWFD-UHFFFAOYSA-N 2-amino-5-methyl-1,4-diphenylpyrrole-3-carbonitrile Chemical compound CC1=C(C=2C=CC=CC=2)C(C#N)=C(N)N1C1=CC=CC=C1 UBIUANGMGZYWFD-UHFFFAOYSA-N 0.000 description 3
- WEZAHYDFZNTGKE-UHFFFAOYSA-N 3-ethoxyaniline Chemical compound CCOC1=CC=CC(N)=C1 WEZAHYDFZNTGKE-UHFFFAOYSA-N 0.000 description 3
- 125000001137 3-hydroxypropoxy group Chemical group [H]OC([H])([H])C([H])([H])C([H])([H])O* 0.000 description 3
- JJSOEXSBZGKGIF-UHFFFAOYSA-N 7-[3-(3-chloropropoxy)phenyl]-5-(3-phenylmethoxyphenyl)pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1=2C(N)=NC=NC=2N(C=2C=C(OCCCCl)C=CC=2)C=C1C(C=1)=CC=CC=1OCC1=CC=CC=C1 JJSOEXSBZGKGIF-UHFFFAOYSA-N 0.000 description 3
- 239000005711 Benzoic acid Substances 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- 235000010233 benzoic acid Nutrition 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 125000001589 carboacyl group Chemical group 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
- 239000000460 chlorine Substances 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 125000005842 heteroatom Chemical group 0.000 description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- 229920001592 potato starch Polymers 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000011200 topical administration Methods 0.000 description 3
- APWRZPQBPCAXFP-UHFFFAOYSA-N 1-(1-oxo-2H-isoquinolin-5-yl)-5-(trifluoromethyl)-N-[2-(trifluoromethyl)pyridin-4-yl]pyrazole-4-carboxamide Chemical compound O=C1NC=CC2=C(C=CC=C12)N1N=CC(=C1C(F)(F)F)C(=O)NC1=CC(=NC=C1)C(F)(F)F APWRZPQBPCAXFP-UHFFFAOYSA-N 0.000 description 2
- UUWJBXKHMMQDED-UHFFFAOYSA-N 1-(3-chlorophenyl)ethanone Chemical compound CC(=O)C1=CC=CC(Cl)=C1 UUWJBXKHMMQDED-UHFFFAOYSA-N 0.000 description 2
- LFLLXWJQAMGJCE-UHFFFAOYSA-N 1-[2-(3-ethoxyanilino)phenyl]ethanone Chemical compound CCOC1=CC=CC(NC=2C(=CC=CC=2)C(C)=O)=C1 LFLLXWJQAMGJCE-UHFFFAOYSA-N 0.000 description 2
- IEGASWPUWJWBDQ-UHFFFAOYSA-N 1-[2-(3-phenylmethoxyanilino)phenyl]ethanone Chemical compound CC(=O)C1=CC=CC=C1NC1=CC=CC(OCC=2C=CC=CC=2)=C1 IEGASWPUWJWBDQ-UHFFFAOYSA-N 0.000 description 2
- WMASLRCNNKMRFP-UHFFFAOYSA-N 1-fluoro-3-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC(F)=C1 WMASLRCNNKMRFP-UHFFFAOYSA-N 0.000 description 2
- CJNPJKYCHRKYHU-UHFFFAOYSA-N 2-amino-1,4-diphenylpyrrole-3-carbonitrile Chemical compound NC1=C(C#N)C(C=2C=CC=CC=2)=CN1C1=CC=CC=C1 CJNPJKYCHRKYHU-UHFFFAOYSA-N 0.000 description 2
- HEQOJEGTZCTHCF-UHFFFAOYSA-N 2-amino-1-phenylethanone Chemical compound NCC(=O)C1=CC=CC=C1 HEQOJEGTZCTHCF-UHFFFAOYSA-N 0.000 description 2
- CXUDDVLSISMCMU-UHFFFAOYSA-N 2-amino-4-(3,5-dimethoxyphenyl)-1-phenylpyrrole-3-carbonitrile Chemical compound COC1=CC(OC)=CC(C=2C(=C(N)N(C=2)C=2C=CC=CC=2)C#N)=C1 CXUDDVLSISMCMU-UHFFFAOYSA-N 0.000 description 2
- XZNAQKWHERBNFZ-UHFFFAOYSA-N 2-amino-4-(3-chlorophenyl)-1-phenylpyrrole-3-carbonitrile Chemical compound NC1=C(C#N)C(C=2C=C(Cl)C=CC=2)=CN1C1=CC=CC=C1 XZNAQKWHERBNFZ-UHFFFAOYSA-N 0.000 description 2
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 2
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 2
- VHPOIICDRDUTEX-UHFFFAOYSA-N 4-[4-amino-7-[3-(2-imidazol-1-ylethoxy)phenyl]pyrrolo[2,3-d]pyrimidin-5-yl]-2,6-dimethylphenol Chemical compound CC1=C(O)C(C)=CC(C=2C3=C(N)N=CN=C3N(C=3C=C(OCCN4C=NC=C4)C=CC=3)C=2)=C1 VHPOIICDRDUTEX-UHFFFAOYSA-N 0.000 description 2
- 229940073735 4-hydroxy acetophenone Drugs 0.000 description 2
- LXBHHIZIQVZGFN-UHFFFAOYSA-N 4-hydroxy-3-methylacetophenone Chemical compound CC(=O)C1=CC=C(O)C(C)=C1 LXBHHIZIQVZGFN-UHFFFAOYSA-N 0.000 description 2
- IQWBSXZPXUSEFK-UHFFFAOYSA-N 5-(3-chlorophenyl)-7-[3-(2-imidazol-1-ylethoxy)phenyl]pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1=2C(N)=NC=NC=2N(C=2C=C(OCCN3C=NC=C3)C=CC=2)C=C1C1=CC=CC(Cl)=C1 IQWBSXZPXUSEFK-UHFFFAOYSA-N 0.000 description 2
- NEPKHYMFOUGGAN-UHFFFAOYSA-N 5-[4-amino-7-[3-(2-imidazol-1-ylethoxy)phenyl]pyrrolo[2,3-d]pyrimidin-5-yl]-2-methoxyphenol Chemical compound C1=C(O)C(OC)=CC=C1C(C1=C(N)N=CN=C11)=CN1C1=CC=CC(OCCN2C=NC=C2)=C1 NEPKHYMFOUGGAN-UHFFFAOYSA-N 0.000 description 2
- LQJXRKHBACXEJA-UHFFFAOYSA-N 5-phenyl-7-[3-[(2-piperazin-1-ylethylamino)methyl]phenyl]pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1=2C(N)=NC=NC=2N(C=2C=C(CNCCN3CCNCC3)C=CC=2)C=C1C1=CC=CC=C1 LQJXRKHBACXEJA-UHFFFAOYSA-N 0.000 description 2
- KMCDOZNNKQIWER-UHFFFAOYSA-N 6-methyl-5,7-diphenylpyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C12=C(N)N=CN=C2N(C=2C=CC=CC=2)C(C)=C1C1=CC=CC=C1 KMCDOZNNKQIWER-UHFFFAOYSA-N 0.000 description 2
- RGXZELZLEZEAKE-UHFFFAOYSA-N 7-[3-(2-chloroethoxy)phenyl]-5-(3-methyl-4-phenylmethoxyphenyl)pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound CC1=CC(C=2C3=C(N)N=CN=C3N(C=3C=C(OCCCl)C=CC=3)C=2)=CC=C1OCC1=CC=CC=C1 RGXZELZLEZEAKE-UHFFFAOYSA-N 0.000 description 2
- PHNITJIJYJGCDS-UHFFFAOYSA-N 7-[3-(2-chloroethoxy)phenyl]-5-phenylpyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1=2C(N)=NC=NC=2N(C=2C=C(OCCCl)C=CC=2)C=C1C1=CC=CC=C1 PHNITJIJYJGCDS-UHFFFAOYSA-N 0.000 description 2
- PJUHAYIMLDQYHA-UHFFFAOYSA-N 7-[3-(2-imidazol-1-ylethoxy)phenyl]-5-(3-phenylmethoxyphenyl)pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1=2C(N)=NC=NC=2N(C=2C=C(OCCN3C=NC=C3)C=CC=2)C=C1C(C=1)=CC=CC=1OCC1=CC=CC=C1 PJUHAYIMLDQYHA-UHFFFAOYSA-N 0.000 description 2
- BZLNUXBAPKSAAE-UHFFFAOYSA-N 7-[3-(3-chloropropoxy)phenyl]-5-(4-phenylmethoxyphenyl)pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1=2C(N)=NC=NC=2N(C=2C=C(OCCCCl)C=CC=2)C=C1C(C=C1)=CC=C1OCC1=CC=CC=C1 BZLNUXBAPKSAAE-UHFFFAOYSA-N 0.000 description 2
- LRHUPZZNDXNPMR-UHFFFAOYSA-N 7-[4-(2-chloroethoxy)phenyl]-5-(3-phenylmethoxyphenyl)pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1=2C(N)=NC=NC=2N(C=2C=CC(OCCCl)=CC=2)C=C1C(C=1)=CC=CC=1OCC1=CC=CC=C1 LRHUPZZNDXNPMR-UHFFFAOYSA-N 0.000 description 2
- PEHVGBZKEYRQSX-UHFFFAOYSA-N 7-deaza-adenine Chemical compound NC1=NC=NC2=C1C=CN2 PEHVGBZKEYRQSX-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 2
- MFESCIUQSIBMSM-UHFFFAOYSA-N I-BCP Chemical compound ClCCCBr MFESCIUQSIBMSM-UHFFFAOYSA-N 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 2
- YVDSCAPXSLVWCG-UHFFFAOYSA-N OCCC[S] Chemical compound OCCC[S] YVDSCAPXSLVWCG-UHFFFAOYSA-N 0.000 description 2
- IDRGFNPZDVBSSE-UHFFFAOYSA-N OCCN1CCN(CC1)c1ccc(Nc2ncc3cccc(-c4cccc(NC(=O)C=C)c4)c3n2)c(F)c1F Chemical compound OCCN1CCN(CC1)c1ccc(Nc2ncc3cccc(-c4cccc(NC(=O)C=C)c4)c3n2)c(F)c1F IDRGFNPZDVBSSE-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 240000006394 Sorghum bicolor Species 0.000 description 2
- 235000011684 Sorghum saccharatum Nutrition 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- XAKBSHICSHRJCL-UHFFFAOYSA-N [CH2]C(=O)C1=CC=CC=C1 Chemical group [CH2]C(=O)C1=CC=CC=C1 XAKBSHICSHRJCL-UHFFFAOYSA-N 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 150000001335 aliphatic alkanes Chemical class 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 150000003927 aminopyridines Chemical class 0.000 description 2
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- NEHMKBQYUWJMIP-NJFSPNSNSA-N chloro(114C)methane Chemical compound [14CH3]Cl NEHMKBQYUWJMIP-NJFSPNSNSA-N 0.000 description 2
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- QTMDXZNDVAMKGV-UHFFFAOYSA-L copper(ii) bromide Chemical compound [Cu+2].[Br-].[Br-] QTMDXZNDVAMKGV-UHFFFAOYSA-L 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 125000001033 ether group Chemical group 0.000 description 2
- 239000010685 fatty oil Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000007941 film coated tablet Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 125000001475 halogen functional group Chemical group 0.000 description 2
- IXCSERBJSXMMFS-UHFFFAOYSA-N hcl hcl Chemical compound Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
- 210000004124 hock Anatomy 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- ZGEGCLOFRBLKSE-UHFFFAOYSA-N methylene hexane Natural products CCCCCC=C ZGEGCLOFRBLKSE-UHFFFAOYSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- SVEUVITYHIHZQE-UHFFFAOYSA-N n-methylpyridin-2-amine Chemical compound CNC1=CC=CC=N1 SVEUVITYHIHZQE-UHFFFAOYSA-N 0.000 description 2
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 2
- 125000003261 o-tolyl group Chemical group [H]C1=C([H])C(*)=C(C([H])=C1[H])C([H])([H])[H] 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 2
- 238000006798 ring closing metathesis reaction Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000002511 suppository base Substances 0.000 description 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- VCGRFBXVSFAGGA-UHFFFAOYSA-N (1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone Chemical compound CC=1ON=C(C=2C=CC(F)=CC=2)C=1COC(N=C1)=CC=C1C(=O)N1CCS(=O)(=O)CC1 VCGRFBXVSFAGGA-UHFFFAOYSA-N 0.000 description 1
- AAWZDTNXLSGCEK-LNVDRNJUSA-N (3r,5r)-1,3,4,5-tetrahydroxycyclohexane-1-carboxylic acid Chemical compound O[C@@H]1CC(O)(C(O)=O)C[C@@H](O)C1O AAWZDTNXLSGCEK-LNVDRNJUSA-N 0.000 description 1
- ZGYIXVSQHOKQRZ-COIATFDQSA-N (e)-n-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]-3-cyano-7-[(3s)-oxolan-3-yl]oxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide Chemical compound N#CC1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC(C=C1Cl)=CC=C1OCC1=CC=CC=N1 ZGYIXVSQHOKQRZ-COIATFDQSA-N 0.000 description 1
- MOWXJLUYGFNTAL-DEOSSOPVSA-N (s)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxypyridazin-3-yl)methanol Chemical compound N1=NC(OC)=CC=C1[C@@H](O)C1=CC(C=2C3=CC=C(C=C3N=CN=2)N2CCOCC2)=C(F)C=C1Cl MOWXJLUYGFNTAL-DEOSSOPVSA-N 0.000 description 1
- FBMZEITWVNHWJW-UHFFFAOYSA-N 1,7-dihydropyrrolo[2,3-d]pyrimidin-4-one Chemical compound OC1=NC=NC2=C1C=CN2 FBMZEITWVNHWJW-UHFFFAOYSA-N 0.000 description 1
- MCWMFKKGQWBJEL-UHFFFAOYSA-N 1-(2-anilinophenyl)-2-chloroethanone Chemical compound ClCC(=O)C1=CC=CC=C1NC1=CC=CC=C1 MCWMFKKGQWBJEL-UHFFFAOYSA-N 0.000 description 1
- SHCPPNUKVMYGIU-UHFFFAOYSA-N 1-(2-bromophenyl)-2-chloroethanone Chemical compound ClCC(=O)C1=CC=CC=C1Br SHCPPNUKVMYGIU-UHFFFAOYSA-N 0.000 description 1
- SFCCOHHWKRVDHH-UHFFFAOYSA-N 1-(2-bromophenyl)propan-1-one Chemical compound CCC(=O)C1=CC=CC=C1Br SFCCOHHWKRVDHH-UHFFFAOYSA-N 0.000 description 1
- YJKHOUIVWKQRSL-UHFFFAOYSA-N 1-(3,5-dimethoxyphenyl)ethanone Chemical compound COC1=CC(OC)=CC(C(C)=O)=C1 YJKHOUIVWKQRSL-UHFFFAOYSA-N 0.000 description 1
- ABDDQTDRAHXHOC-QMMMGPOBSA-N 1-[(7s)-5,7-dihydro-4h-thieno[2,3-c]pyran-7-yl]-n-methylmethanamine Chemical compound CNC[C@@H]1OCCC2=C1SC=C2 ABDDQTDRAHXHOC-QMMMGPOBSA-N 0.000 description 1
- GQIRIWDEZSKOCN-UHFFFAOYSA-N 1-chloro-n,n,2-trimethylprop-1-en-1-amine Chemical compound CN(C)C(Cl)=C(C)C GQIRIWDEZSKOCN-UHFFFAOYSA-N 0.000 description 1
- MRSDBRAGNWAUPL-UHFFFAOYSA-N 1-phenyl-2-phenylmethoxyethanone Chemical compound C=1C=CC=CC=1C(=O)COCC1=CC=CC=C1 MRSDBRAGNWAUPL-UHFFFAOYSA-N 0.000 description 1
- YXWWHNCQZBVZPV-UHFFFAOYSA-N 2'-methylacetophenone Chemical compound CC(=O)C1=CC=CC=C1C YXWWHNCQZBVZPV-UHFFFAOYSA-N 0.000 description 1
- PRMZVGDZZPRZIF-UHFFFAOYSA-N 2-(3-aminophenoxy)ethanol Chemical compound NC1=CC=CC(OCCO)=C1 PRMZVGDZZPRZIF-UHFFFAOYSA-N 0.000 description 1
- ANVULTHPMNCMCQ-UHFFFAOYSA-N 2-(4-amino-5-phenylpyrrolo[2,3-d]pyrimidin-7-yl)phenol Chemical compound C1=2C(N)=NC=NC=2N(C=2C(=CC=CC=2)O)C=C1C1=CC=CC=C1 ANVULTHPMNCMCQ-UHFFFAOYSA-N 0.000 description 1
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 1
- BHXPCSYUCMHKLS-UHFFFAOYSA-N 2-[2-[3-(4-amino-5-phenylpyrrolo[2,3-d]pyrimidin-7-yl)phenoxy]ethylamino]ethanol Chemical compound C1=2C(N)=NC=NC=2N(C=2C=C(OCCNCCO)C=CC=2)C=C1C1=CC=CC=C1 BHXPCSYUCMHKLS-UHFFFAOYSA-N 0.000 description 1
- CFVRCEJUBLZVPR-UHFFFAOYSA-N 2-[2-[4-(4-amino-5-phenylpyrrolo[2,3-d]pyrimidin-7-yl)phenoxy]ethylamino]ethanol Chemical compound C1=2C(N)=NC=NC=2N(C=2C=CC(OCCNCCO)=CC=2)C=C1C1=CC=CC=C1 CFVRCEJUBLZVPR-UHFFFAOYSA-N 0.000 description 1
- HYUKRGIIHHEYLH-UHFFFAOYSA-N 2-[3-(4-amino-5-phenylpyrrolo[2,3-d]pyrimidin-7-yl)phenoxy]ethyl formate Chemical compound C1=2C(N)=NC=NC=2N(C=2C=C(OCCOC=O)C=CC=2)C=C1C1=CC=CC=C1 HYUKRGIIHHEYLH-UHFFFAOYSA-N 0.000 description 1
- XLXHPZXWSIRIDL-UHFFFAOYSA-N 2-[3-[4-amino-5-(3-methoxyphenyl)pyrrolo[2,3-d]pyrimidin-7-yl]phenoxy]ethanol Chemical compound COC1=CC=CC(C=2C3=C(N)N=CN=C3N(C=3C=C(OCCO)C=CC=3)C=2)=C1 XLXHPZXWSIRIDL-UHFFFAOYSA-N 0.000 description 1
- JQYSTOYXBGWIAE-UHFFFAOYSA-N 2-[3-[4-amino-5-(4-fluorophenyl)pyrrolo[2,3-d]pyrimidin-7-yl]phenoxy]ethanol Chemical compound C1=2C(N)=NC=NC=2N(C=2C=C(OCCO)C=CC=2)C=C1C1=CC=C(F)C=C1 JQYSTOYXBGWIAE-UHFFFAOYSA-N 0.000 description 1
- BPFLYCGSQAYKOA-UHFFFAOYSA-N 2-[3-[4-amino-5-(4-methoxyphenyl)pyrrolo[2,3-d]pyrimidin-7-yl]phenoxy]ethanol Chemical compound C1=CC(OC)=CC=C1C(C1=C(N)N=CN=C11)=CN1C1=CC=CC(OCCO)=C1 BPFLYCGSQAYKOA-UHFFFAOYSA-N 0.000 description 1
- IVQMEAKPRYYGBI-UHFFFAOYSA-N 2-[4-[4-amino-5-(3-methoxyphenyl)pyrrolo[2,3-d]pyrimidin-7-yl]phenoxy]ethanol Chemical compound COC1=CC=CC(C=2C3=C(N)N=CN=C3N(C=3C=CC(OCCO)=CC=3)C=2)=C1 IVQMEAKPRYYGBI-UHFFFAOYSA-N 0.000 description 1
- RQAFMLCWWGDNLI-UHFFFAOYSA-N 2-[4-[bis(2-chloroethyl)amino]phenyl]acetic acid Chemical compound OC(=O)CC1=CC=C(N(CCCl)CCCl)C=C1 RQAFMLCWWGDNLI-UHFFFAOYSA-N 0.000 description 1
- AHYOOVUZBYBFLE-UHFFFAOYSA-N 2-[[2-(4-amino-5-phenylpyrrolo[2,3-d]pyrimidin-7-yl)phenyl]methylsulfanyl]ethanol Chemical compound C1=2C(N)=NC=NC=2N(C=2C(=CC=CC=2)CSCCO)C=C1C1=CC=CC=C1 AHYOOVUZBYBFLE-UHFFFAOYSA-N 0.000 description 1
- CTJXPMKWJHVTCX-UHFFFAOYSA-N 2-[[3-(4-amino-5-phenylpyrrolo[2,3-d]pyrimidin-7-yl)phenyl]methylsulfanyl]ethanol Chemical compound C1=2C(N)=NC=NC=2N(C=2C=C(CSCCO)C=CC=2)C=C1C1=CC=CC=C1 CTJXPMKWJHVTCX-UHFFFAOYSA-N 0.000 description 1
- KCEMBBWZETWXEF-UHFFFAOYSA-N 2-[[3-[4-amino-5-(3-methoxyphenyl)pyrrolo[2,3-d]pyrimidin-7-yl]phenyl]methylamino]ethanol Chemical compound COC1=CC=CC(C=2C3=C(N)N=CN=C3N(C=3C=C(CNCCO)C=CC=3)C=2)=C1 KCEMBBWZETWXEF-UHFFFAOYSA-N 0.000 description 1
- LITLHSGRXNGRTE-UHFFFAOYSA-N 2-[[4-(4-amino-5-phenylpyrrolo[2,3-d]pyrimidin-7-yl)phenyl]methylsulfanyl]ethanol Chemical compound C1=2C(N)=NC=NC=2N(C=2C=CC(CSCCO)=CC=2)C=C1C1=CC=CC=C1 LITLHSGRXNGRTE-UHFFFAOYSA-N 0.000 description 1
- SOGPAYHSZLZSSV-UHFFFAOYSA-N 2-amino-1,4-bis(4-fluorophenyl)pyrrole-3-carbonitrile Chemical compound NC1=C(C#N)C(C=2C=CC(F)=CC=2)=CN1C1=CC=C(F)C=C1 SOGPAYHSZLZSSV-UHFFFAOYSA-N 0.000 description 1
- YZUIUIXBNCDKRP-UHFFFAOYSA-N 2-amino-1-(3-ethoxyphenyl)-4-phenylpyrrole-3-carbonitrile Chemical compound CCOC1=CC=CC(N2C(=C(C#N)C(=C2)C=2C=CC=CC=2)N)=C1 YZUIUIXBNCDKRP-UHFFFAOYSA-N 0.000 description 1
- HGUUICKROVJTES-UHFFFAOYSA-N 2-amino-1h-pyrrole-3-carbonitrile Chemical compound NC=1NC=CC=1C#N HGUUICKROVJTES-UHFFFAOYSA-N 0.000 description 1
- JZERAGFMKPXESB-UHFFFAOYSA-N 2-amino-4-(1,3-benzodioxol-5-yl)-1-(3-ethoxyphenyl)pyrrole-3-carbonitrile Chemical compound CCOC1=CC=CC(N2C(=C(C#N)C(=C2)C=2C=C3OCOC3=CC=2)N)=C1 JZERAGFMKPXESB-UHFFFAOYSA-N 0.000 description 1
- BAXGGYADLVIMSY-UHFFFAOYSA-N 2-amino-4-(2-chlorophenyl)-1-phenylpyrrole-3-carbonitrile Chemical compound NC1=C(C#N)C(C=2C(=CC=CC=2)Cl)=CN1C1=CC=CC=C1 BAXGGYADLVIMSY-UHFFFAOYSA-N 0.000 description 1
- KSCCPKQSGPCICI-UHFFFAOYSA-N 2-amino-4-(2-methylphenyl)-1-phenylpyrrole-3-carbonitrile Chemical compound CC1=CC=CC=C1C1=CN(C=2C=CC=CC=2)C(N)=C1C#N KSCCPKQSGPCICI-UHFFFAOYSA-N 0.000 description 1
- SOSQWBUZLJUNRQ-UHFFFAOYSA-N 2-amino-4-(4-fluorophenyl)-1-phenylpyrrole-3-carbonitrile Chemical compound NC1=C(C#N)C(C=2C=CC(F)=CC=2)=CN1C1=CC=CC=C1 SOSQWBUZLJUNRQ-UHFFFAOYSA-N 0.000 description 1
- IICGEDJQTYOLNT-UHFFFAOYSA-N 2-amino-4-phenyl-1-(3-phenylmethoxyphenyl)pyrrole-3-carbonitrile Chemical compound NC1=C(C#N)C(C=2C=CC=CC=2)=CN1C(C=1)=CC=CC=1OCC1=CC=CC=C1 IICGEDJQTYOLNT-UHFFFAOYSA-N 0.000 description 1
- JXJWKJVLYQJYTN-UHFFFAOYSA-N 2-anilino-1-phenylpropan-1-one Chemical compound C=1C=CC=CC=1C(=O)C(C)NC1=CC=CC=C1 JXJWKJVLYQJYTN-UHFFFAOYSA-N 0.000 description 1
- KJVRURZDIOVSSQ-UHFFFAOYSA-N 2-bromo-1-(3-chlorophenyl)ethanone Chemical compound ClC1=CC=CC(C(=O)CBr)=C1 KJVRURZDIOVSSQ-UHFFFAOYSA-N 0.000 description 1
- IOOHBIFQNQQUFI-UHFFFAOYSA-N 2-bromo-1-(3-methoxyphenyl)ethanone Chemical compound COC1=CC=CC(C(=O)CBr)=C1 IOOHBIFQNQQUFI-UHFFFAOYSA-N 0.000 description 1
- GFZOJLIHCWKKPR-UHFFFAOYSA-N 2-bromo-1-(3-phenylmethoxyphenyl)ethanone Chemical compound BrCC(=O)C1=CC=CC(OCC=2C=CC=CC=2)=C1 GFZOJLIHCWKKPR-UHFFFAOYSA-N 0.000 description 1
- IAPCKPXQFYWNDN-UHFFFAOYSA-N 2-bromo-1-(4-phenylmethoxyphenyl)ethanone Chemical compound C1=CC(C(=O)CBr)=CC=C1OCC1=CC=CC=C1 IAPCKPXQFYWNDN-UHFFFAOYSA-N 0.000 description 1
- UJZWJOQRSMOFMA-UHFFFAOYSA-N 2-chloro-1-(4-fluorophenyl)ethanone Chemical compound FC1=CC=C(C(=O)CCl)C=C1 UJZWJOQRSMOFMA-UHFFFAOYSA-N 0.000 description 1
- IQUPABOKLQSFBK-UHFFFAOYSA-N 2-nitrophenol Chemical compound OC1=CC=CC=C1[N+]([O-])=O IQUPABOKLQSFBK-UHFFFAOYSA-N 0.000 description 1
- ZSLUVFAKFWKJRC-IGMARMGPSA-N 232Th Chemical compound [232Th] ZSLUVFAKFWKJRC-IGMARMGPSA-N 0.000 description 1
- BMHMKWXYXFBWMI-UHFFFAOYSA-N 3,4-Methylenedioxyacetophenone Chemical compound CC(=O)C1=CC=C2OCOC2=C1 BMHMKWXYXFBWMI-UHFFFAOYSA-N 0.000 description 1
- 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 description 1
- HCDMJFOHIXMBOV-UHFFFAOYSA-N 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one Chemical compound C=1C2=C3N(CC)C(=O)N(C=4C(=C(OC)C=C(OC)C=4F)F)CC3=CN=C2NC=1CN1CCOCC1 HCDMJFOHIXMBOV-UHFFFAOYSA-N 0.000 description 1
- RNNUSMIPHMAFKN-UHFFFAOYSA-N 3-(2-methoxyethoxy)aniline Chemical compound COCCOC1=CC=CC(N)=C1 RNNUSMIPHMAFKN-UHFFFAOYSA-N 0.000 description 1
- ZPRMEOZLMLXKQP-UHFFFAOYSA-N 3-(4-amino-5-phenylpyrrolo[2,3-d]pyrimidin-7-yl)phenol Chemical compound C1=2C(N)=NC=NC=2N(C=2C=C(O)C=CC=2)C=C1C1=CC=CC=C1 ZPRMEOZLMLXKQP-UHFFFAOYSA-N 0.000 description 1
- BYHQTRFJOGIQAO-GOSISDBHSA-N 3-(4-bromophenyl)-8-[(2R)-2-hydroxypropyl]-1-[(3-methoxyphenyl)methyl]-1,3,8-triazaspiro[4.5]decan-2-one Chemical compound C[C@H](CN1CCC2(CC1)CN(C(=O)N2CC3=CC(=CC=C3)OC)C4=CC=C(C=C4)Br)O BYHQTRFJOGIQAO-GOSISDBHSA-N 0.000 description 1
- BVNBAWHBWPQCSG-UHFFFAOYSA-N 3-[3-(4-amino-5-phenylpyrrolo[2,3-d]pyrimidin-7-yl)phenyl]sulfanylpropan-1-ol Chemical compound C1=2C(N)=NC=NC=2N(C=2C=C(SCCCO)C=CC=2)C=C1C1=CC=CC=C1 BVNBAWHBWPQCSG-UHFFFAOYSA-N 0.000 description 1
- MXXAUHPHHQVZPK-UHFFFAOYSA-N 3-[3-(4-amino-5-phenylpyrrolo[2,3-d]pyrimidin-7-yl)phenyl]sulfonylpropan-1-ol Chemical compound C1=2C(N)=NC=NC=2N(C=2C=C(C=CC=2)S(=O)(=O)CCCO)C=C1C1=CC=CC=C1 MXXAUHPHHQVZPK-UHFFFAOYSA-N 0.000 description 1
- WNEODWDFDXWOLU-QHCPKHFHSA-N 3-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(2s)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl]amino]-6-oxopyridin-3-yl]pyridin-2-yl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one Chemical compound C([C@@H](N(CC1)C=2C=NC(NC=3C(N(C)C=C(C=3)C=3C(=C(N4C(C5=CC=6CC(C)(C)CC=6N5CC4)=O)N=CC=3)CO)=O)=CC=2)C)N1C1COC1 WNEODWDFDXWOLU-QHCPKHFHSA-N 0.000 description 1
- SRVXSISGYBMIHR-UHFFFAOYSA-N 3-[3-[3-(2-amino-2-oxoethyl)phenyl]-5-chlorophenyl]-3-(5-methyl-1,3-thiazol-2-yl)propanoic acid Chemical compound S1C(C)=CN=C1C(CC(O)=O)C1=CC(Cl)=CC(C=2C=C(CC(N)=O)C=CC=2)=C1 SRVXSISGYBMIHR-UHFFFAOYSA-N 0.000 description 1
- DDMXECNPNSJOGX-UHFFFAOYSA-N 3-[3-[4-amino-5-(3-methoxyphenyl)pyrrolo[2,3-d]pyrimidin-7-yl]phenoxy]propan-1-ol Chemical compound COC1=CC=CC(C=2C3=C(N)N=CN=C3N(C=3C=C(OCCCO)C=CC=3)C=2)=C1 DDMXECNPNSJOGX-UHFFFAOYSA-N 0.000 description 1
- NLMNBWNLZIXVDK-UHFFFAOYSA-N 3-[4-(4-amino-5-phenylpyrrolo[2,3-d]pyrimidin-7-yl)phenyl]sulfonylpropan-1-ol Chemical compound C1=2C(N)=NC=NC=2N(C=2C=CC(=CC=2)S(=O)(=O)CCCO)C=C1C1=CC=CC=C1 NLMNBWNLZIXVDK-UHFFFAOYSA-N 0.000 description 1
- XNVIWOLUGGBNCM-UHFFFAOYSA-N 3-[4-[4-amino-5-(3-methoxyphenyl)pyrrolo[2,3-d]pyrimidin-7-yl]phenoxy]propan-1-ol Chemical compound COC1=CC=CC(C=2C3=C(N)N=CN=C3N(C=3C=CC(OCCCO)=CC=3)C=2)=C1 XNVIWOLUGGBNCM-UHFFFAOYSA-N 0.000 description 1
- MLNDBMAIGFXEBM-UHFFFAOYSA-N 3-[4-amino-7-[3-(2-aminoethoxy)phenyl]pyrrolo[2,3-d]pyrimidin-5-yl]phenol Chemical compound NCCOC1=CC=CC(N2C3=NC=NC(N)=C3C(C=3C=C(O)C=CC=3)=C2)=C1 MLNDBMAIGFXEBM-UHFFFAOYSA-N 0.000 description 1
- JSRWNJYLWOAFBC-UHFFFAOYSA-N 3-[4-amino-7-[4-(2-aminoethoxy)phenyl]pyrrolo[2,3-d]pyrimidin-5-yl]phenol Chemical compound C1=CC(OCCN)=CC=C1N1C2=NC=NC(N)=C2C(C=2C=C(O)C=CC=2)=C1 JSRWNJYLWOAFBC-UHFFFAOYSA-N 0.000 description 1
- ZLWLGAHYICQJMI-UHFFFAOYSA-N 3-[4-amino-7-[4-[2-(2-hydroxyethylamino)ethoxy]phenyl]pyrrolo[2,3-d]pyrimidin-5-yl]phenol Chemical compound C1=2C(N)=NC=NC=2N(C=2C=CC(OCCNCCO)=CC=2)C=C1C1=CC=CC(O)=C1 ZLWLGAHYICQJMI-UHFFFAOYSA-N 0.000 description 1
- GSXUEJSPPHAKQL-UHFFFAOYSA-N 3-[[2-(4-amino-5-phenylpyrrolo[2,3-d]pyrimidin-7-yl)phenyl]methylamino]propan-1-ol Chemical compound C1=2C(N)=NC=NC=2N(C=2C(=CC=CC=2)CNCCCO)C=C1C1=CC=CC=C1 GSXUEJSPPHAKQL-UHFFFAOYSA-N 0.000 description 1
- HTDNAMBHEVONFG-UHFFFAOYSA-N 3-[[3-(4-amino-5-phenylpyrrolo[2,3-d]pyrimidin-7-yl)phenyl]methylamino]propan-1-ol Chemical compound C1=2C(N)=NC=NC=2N(C=2C=C(CNCCCO)C=CC=2)C=C1C1=CC=CC=C1 HTDNAMBHEVONFG-UHFFFAOYSA-N 0.000 description 1
- BIVUMPOPFIQNQQ-UHFFFAOYSA-N 3-[[4-(4-amino-5-phenylpyrrolo[2,3-d]pyrimidin-7-yl)phenyl]methylamino]propan-1-ol Chemical compound C1=2C(N)=NC=NC=2N(C=2C=CC(CNCCCO)=CC=2)C=C1C1=CC=CC=C1 BIVUMPOPFIQNQQ-UHFFFAOYSA-N 0.000 description 1
- QOXOZONBQWIKDA-UHFFFAOYSA-N 3-hydroxypropyl Chemical group [CH2]CCO QOXOZONBQWIKDA-UHFFFAOYSA-N 0.000 description 1
- IGPFOKFDBICQMC-UHFFFAOYSA-N 3-phenylmethoxyaniline Chemical compound NC1=CC=CC(OCC=2C=CC=CC=2)=C1 IGPFOKFDBICQMC-UHFFFAOYSA-N 0.000 description 1
- JQRJWBDPSJFJPY-UHFFFAOYSA-N 4-(2-chloroethoxy)aniline Chemical compound NC1=CC=C(OCCCl)C=C1 JQRJWBDPSJFJPY-UHFFFAOYSA-N 0.000 description 1
- ORBMDVCSOGRFIA-UHFFFAOYSA-N 4-(4-amino-5-phenylpyrrolo[2,3-d]pyrimidin-7-yl)phenol Chemical compound C1=2C(N)=NC=NC=2N(C=2C=CC(O)=CC=2)C=C1C1=CC=CC=C1 ORBMDVCSOGRFIA-UHFFFAOYSA-N 0.000 description 1
- NPBYWTHIHISZHL-UHFFFAOYSA-N 4-(4-amino-7-phenylpyrrolo[2,3-d]pyrimidin-5-yl)-2-methylphenol Chemical compound C1=C(O)C(C)=CC(C=2C3=C(N)N=CN=C3N(C=3C=CC=CC=3)C=2)=C1 NPBYWTHIHISZHL-UHFFFAOYSA-N 0.000 description 1
- QPXIFQCXFJLQCE-UHFFFAOYSA-N 4-(4-amino-7-phenylpyrrolo[2,3-d]pyrimidin-5-yl)phenol Chemical compound C1=2C(N)=NC=NC=2N(C=2C=CC=CC=2)C=C1C1=CC=C(O)C=C1 QPXIFQCXFJLQCE-UHFFFAOYSA-N 0.000 description 1
- JOQBKYOOFMIJCS-UHFFFAOYSA-N 4-[4-amino-7-(1,3-benzodioxol-5-yl)pyrrolo[2,3-d]pyrimidin-5-yl]phenol Chemical compound C1=2C(N)=NC=NC=2N(C=2C=C3OCOC3=CC=2)C=C1C1=CC=C(O)C=C1 JOQBKYOOFMIJCS-UHFFFAOYSA-N 0.000 description 1
- ZBIUIMNVLBPXSB-UHFFFAOYSA-N 4-[4-amino-7-[3-(2-imidazol-1-ylethoxy)phenyl]pyrrolo[2,3-d]pyrimidin-5-yl]-2-methoxyphenol Chemical compound C1=C(O)C(OC)=CC(C=2C3=C(N)N=CN=C3N(C=3C=C(OCCN4C=NC=C4)C=CC=3)C=2)=C1 ZBIUIMNVLBPXSB-UHFFFAOYSA-N 0.000 description 1
- SYJHOPOSNSWGMG-UHFFFAOYSA-N 4-[4-amino-7-[3-(2-imidazol-1-ylethoxy)phenyl]pyrrolo[2,3-d]pyrimidin-5-yl]-2-methylphenol Chemical compound C1=C(O)C(C)=CC(C=2C3=C(N)N=CN=C3N(C=3C=C(OCCN4C=NC=C4)C=CC=3)C=2)=C1 SYJHOPOSNSWGMG-UHFFFAOYSA-N 0.000 description 1
- JPFAQTJCPDATJA-UHFFFAOYSA-N 4-[4-amino-7-[3-(3-aminopropoxy)phenyl]pyrrolo[2,3-d]pyrimidin-5-yl]phenol Chemical compound NCCCOC1=CC=CC(N2C3=NC=NC(N)=C3C(C=3C=CC(O)=CC=3)=C2)=C1 JPFAQTJCPDATJA-UHFFFAOYSA-N 0.000 description 1
- SHTUTPYCSBXUOI-UHFFFAOYSA-N 4-[4-amino-7-[3-(3-imidazol-1-ylpropoxy)phenyl]pyrrolo[2,3-d]pyrimidin-5-yl]phenol Chemical compound C1=2C(N)=NC=NC=2N(C=2C=C(OCCCN3C=NC=C3)C=CC=2)C=C1C1=CC=C(O)C=C1 SHTUTPYCSBXUOI-UHFFFAOYSA-N 0.000 description 1
- BWKHBQRWLDSXQE-UHFFFAOYSA-N 4-[4-amino-7-[3-[(3-hydroxypropylamino)methyl]phenyl]pyrrolo[2,3-d]pyrimidin-5-yl]phenol Chemical compound C1=2C(N)=NC=NC=2N(C=2C=C(CNCCCO)C=CC=2)C=C1C1=CC=C(O)C=C1 BWKHBQRWLDSXQE-UHFFFAOYSA-N 0.000 description 1
- AHVYHDKFYMUCMU-UHFFFAOYSA-N 4-[4-amino-7-[4-(2-imidazol-1-ylethoxy)phenyl]pyrrolo[2,3-d]pyrimidin-5-yl]phenol Chemical compound C1=2C(N)=NC=NC=2N(C=2C=CC(OCCN3C=NC=C3)=CC=2)C=C1C1=CC=C(O)C=C1 AHVYHDKFYMUCMU-UHFFFAOYSA-N 0.000 description 1
- IJPCTFPNWLVXGU-UHFFFAOYSA-N 4-[4-amino-7-[4-(3-aminopropoxy)phenyl]pyrrolo[2,3-d]pyrimidin-5-yl]phenol Chemical compound C1=CC(OCCCN)=CC=C1N1C2=NC=NC(N)=C2C(C=2C=CC(O)=CC=2)=C1 IJPCTFPNWLVXGU-UHFFFAOYSA-N 0.000 description 1
- KVCQTKNUUQOELD-UHFFFAOYSA-N 4-amino-n-[1-(3-chloro-2-fluoroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=CC(Cl)=C1F KVCQTKNUUQOELD-UHFFFAOYSA-N 0.000 description 1
- 125000004801 4-cyanophenyl group Chemical group [H]C1=C([H])C(C#N)=C([H])C([H])=C1* 0.000 description 1
- SXIFAEWFOJETOA-UHFFFAOYSA-N 4-hydroxy-butyl Chemical group [CH2]CCCO SXIFAEWFOJETOA-UHFFFAOYSA-N 0.000 description 1
- AFVGAHBUCVDPPI-UHFFFAOYSA-N 5,7-diphenylpyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1=2C(N)=NC=NC=2N(C=2C=CC=CC=2)C=C1C1=CC=CC=C1 AFVGAHBUCVDPPI-UHFFFAOYSA-N 0.000 description 1
- ATYJFCXSLJULPH-UHFFFAOYSA-N 5-(2-chlorophenyl)-7-phenylpyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1=2C(N)=NC=NC=2N(C=2C=CC=CC=2)C=C1C1=CC=CC=C1Cl ATYJFCXSLJULPH-UHFFFAOYSA-N 0.000 description 1
- CWUGNRVNSPIEKA-UHFFFAOYSA-N 5-(2-methylphenyl)-7-phenylpyrrolo[2,3-d]pyrimidin-4-amine Chemical compound CC1=CC=CC=C1C(C1=C(N)N=CN=C11)=CN1C1=CC=CC=C1 CWUGNRVNSPIEKA-UHFFFAOYSA-N 0.000 description 1
- XKEJQCXZHXGABT-UHFFFAOYSA-N 5-(3,5-dimethyl-4-phenylmethoxyphenyl)-7-[3-(2-imidazol-1-ylethoxy)phenyl]pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound CC1=CC(C=2C3=C(N)N=CN=C3N(C=3C=C(OCCN4C=NC=C4)C=CC=3)C=2)=CC(C)=C1OCC1=CC=CC=C1 XKEJQCXZHXGABT-UHFFFAOYSA-N 0.000 description 1
- KKYWVNPRFIJNKB-UHFFFAOYSA-N 5-(3-chlorophenyl)-7-phenylpyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1=2C(N)=NC=NC=2N(C=2C=CC=CC=2)C=C1C1=CC=CC(Cl)=C1 KKYWVNPRFIJNKB-UHFFFAOYSA-N 0.000 description 1
- IRPVABHDSJVBNZ-RTHVDDQRSA-N 5-[1-(cyclopropylmethyl)-5-[(1R,5S)-3-(oxetan-3-yl)-3-azabicyclo[3.1.0]hexan-6-yl]pyrazol-3-yl]-3-(trifluoromethyl)pyridin-2-amine Chemical compound C1=C(C(F)(F)F)C(N)=NC=C1C1=NN(CC2CC2)C(C2[C@@H]3CN(C[C@@H]32)C2COC2)=C1 IRPVABHDSJVBNZ-RTHVDDQRSA-N 0.000 description 1
- FVABHFDLMDKJFR-UHFFFAOYSA-N 5-phenyl-7-[4-[(2-piperazin-1-ylethylamino)methyl]phenyl]pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1=2C(N)=NC=NC=2N(C=2C=CC(CNCCN3CCNCC3)=CC=2)C=C1C1=CC=CC=C1 FVABHFDLMDKJFR-UHFFFAOYSA-N 0.000 description 1
- KCBWAFJCKVKYHO-UHFFFAOYSA-N 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-[[4-[1-propan-2-yl-4-(trifluoromethyl)imidazol-2-yl]phenyl]methyl]pyrazolo[3,4-d]pyrimidine Chemical compound C1(CC1)C1=NC=NC(=C1C1=NC=C2C(=N1)N(N=C2)CC1=CC=C(C=C1)C=1N(C=C(N=1)C(F)(F)F)C(C)C)OC KCBWAFJCKVKYHO-UHFFFAOYSA-N 0.000 description 1
- ABUARZAIVWWBRD-UHFFFAOYSA-N 6-bromo-5,7-diphenylpyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1=2C(N)=NC=NC=2N(C=2C=CC=CC=2)C(Br)=C1C1=CC=CC=C1 ABUARZAIVWWBRD-UHFFFAOYSA-N 0.000 description 1
- YRXDIBIYORBPEV-UHFFFAOYSA-N 6-chloro-5,7-diphenylpyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1=2C(N)=NC=NC=2N(C=2C=CC=CC=2)C(Cl)=C1C1=CC=CC=C1 YRXDIBIYORBPEV-UHFFFAOYSA-N 0.000 description 1
- FSICAUYEDVKMSJ-UHFFFAOYSA-N 7-(1,3-benzodioxol-5-yl)-5-phenylpyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1=2C(N)=NC=NC=2N(C=2C=C3OCOC3=CC=2)C=C1C1=CC=CC=C1 FSICAUYEDVKMSJ-UHFFFAOYSA-N 0.000 description 1
- OHVCEWSRYKLXOP-UHFFFAOYSA-N 7-(3-ethoxyphenyl)-5-phenylpyrrolo[2,3-d]pyrimidin-4-amine Chemical compound CCOC1=CC=CC(N2C3=NC=NC(N)=C3C(C=3C=CC=CC=3)=C2)=C1 OHVCEWSRYKLXOP-UHFFFAOYSA-N 0.000 description 1
- OEODULHKELXAFQ-UHFFFAOYSA-N 7-(3-imidazol-1-ylphenyl)-5-phenylpyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1=2C(N)=NC=NC=2N(C=2C=C(C=CC=2)N2C=NC=C2)C=C1C1=CC=CC=C1 OEODULHKELXAFQ-UHFFFAOYSA-N 0.000 description 1
- GKMHXGCRYICCGF-UHFFFAOYSA-N 7-[2-(2-aminoethoxy)phenyl]-5-phenylpyrrolo[2,3-d]pyrimidin-4-amine Chemical compound NCCOC1=CC=CC=C1N1C2=NC=NC(N)=C2C(C=2C=CC=CC=2)=C1 GKMHXGCRYICCGF-UHFFFAOYSA-N 0.000 description 1
- YNLWLVIVDAVULV-UHFFFAOYSA-N 7-[3-(2-aminoethoxy)phenyl]-5-phenylpyrrolo[2,3-d]pyrimidin-4-amine Chemical compound NCCOC1=CC=CC(N2C3=NC=NC(N)=C3C(C=3C=CC=CC=3)=C2)=C1 YNLWLVIVDAVULV-UHFFFAOYSA-N 0.000 description 1
- GWPGYBJCAUTSPC-UHFFFAOYSA-N 7-[3-(2-aminoethylsulfonyl)phenyl]-5-phenylpyrrolo[2,3-d]pyrimidin-4-amine Chemical compound NCCS(=O)(=O)C1=CC=CC(N2C3=NC=NC(N)=C3C(C=3C=CC=CC=3)=C2)=C1 GWPGYBJCAUTSPC-UHFFFAOYSA-N 0.000 description 1
- ADEKZLUAMLAGDO-UHFFFAOYSA-N 7-[3-(2-chloroethoxy)phenyl]-5-(3-chlorophenyl)pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1=2C(N)=NC=NC=2N(C=2C=C(OCCCl)C=CC=2)C=C1C1=CC=CC(Cl)=C1 ADEKZLUAMLAGDO-UHFFFAOYSA-N 0.000 description 1
- ZDYVJMYUORYACM-UHFFFAOYSA-N 7-[3-(2-chloroethoxy)phenyl]-5-(3-methoxy-4-phenylmethoxyphenyl)pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound COC1=CC(C=2C3=C(N)N=CN=C3N(C=3C=C(OCCCl)C=CC=3)C=2)=CC=C1OCC1=CC=CC=C1 ZDYVJMYUORYACM-UHFFFAOYSA-N 0.000 description 1
- OAPWHRCYUVOIPT-UHFFFAOYSA-N 7-[3-(2-chloroethoxy)phenyl]-5-(3-methoxyphenyl)pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound COC1=CC=CC(C=2C3=C(N)N=CN=C3N(C=3C=C(OCCCl)C=CC=3)C=2)=C1 OAPWHRCYUVOIPT-UHFFFAOYSA-N 0.000 description 1
- JDPHDYDEFCDAMM-UHFFFAOYSA-N 7-[3-(2-chloroethoxy)phenyl]-5-(3-phenylmethoxyphenyl)pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1=2C(N)=NC=NC=2N(C=2C=C(OCCCl)C=CC=2)C=C1C(C=1)=CC=CC=1OCC1=CC=CC=C1 JDPHDYDEFCDAMM-UHFFFAOYSA-N 0.000 description 1
- CXJFPCXXKHXJAM-UHFFFAOYSA-N 7-[3-(2-chloroethoxy)phenyl]-5-(4-methoxy-3-phenylmethoxyphenyl)pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound COC1=CC=C(C=2C3=C(N)N=CN=C3N(C=3C=C(OCCCl)C=CC=3)C=2)C=C1OCC1=CC=CC=C1 CXJFPCXXKHXJAM-UHFFFAOYSA-N 0.000 description 1
- BKRRZXZHTARKNQ-UHFFFAOYSA-N 7-[3-(2-imidazol-1-ylethoxy)phenyl]-5-(3-methoxy-4-phenylmethoxyphenyl)pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound COC1=CC(C=2C3=C(N)N=CN=C3N(C=3C=C(OCCN4C=NC=C4)C=CC=3)C=2)=CC=C1OCC1=CC=CC=C1 BKRRZXZHTARKNQ-UHFFFAOYSA-N 0.000 description 1
- NMTVTFKHPNDKFN-UHFFFAOYSA-N 7-[3-(2-imidazol-1-ylethoxy)phenyl]-5-(3-methoxyphenyl)pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound COC1=CC=CC(C=2C3=C(N)N=CN=C3N(C=3C=C(OCCN4C=NC=C4)C=CC=3)C=2)=C1 NMTVTFKHPNDKFN-UHFFFAOYSA-N 0.000 description 1
- HMNBYCPUOHFQLG-UHFFFAOYSA-N 7-[3-(2-imidazol-1-ylethoxy)phenyl]-5-(4-methoxyphenyl)pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1=CC(OC)=CC=C1C(C1=C(N)N=CN=C11)=CN1C1=CC=CC(OCCN2C=NC=C2)=C1 HMNBYCPUOHFQLG-UHFFFAOYSA-N 0.000 description 1
- RKXQVDWEKONPOJ-UHFFFAOYSA-N 7-[3-(2-imidazol-1-ylethoxy)phenyl]-5-(4-phenylmethoxyphenyl)pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1=2C(N)=NC=NC=2N(C=2C=C(OCCN3C=NC=C3)C=CC=2)C=C1C(C=C1)=CC=C1OCC1=CC=CC=C1 RKXQVDWEKONPOJ-UHFFFAOYSA-N 0.000 description 1
- CAQXAMRECFBPCP-UHFFFAOYSA-N 7-[3-(3-aminopropoxy)phenyl]-5-(3-methoxyphenyl)pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound COC1=CC=CC(C=2C3=C(N)N=CN=C3N(C=3C=C(OCCCN)C=CC=3)C=2)=C1 CAQXAMRECFBPCP-UHFFFAOYSA-N 0.000 description 1
- VOZWHXUJKAXJQX-UHFFFAOYSA-N 7-[3-(3-imidazol-1-ylpropoxy)phenyl]-5-(3-phenylmethoxyphenyl)pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1=2C(N)=NC=NC=2N(C=2C=C(OCCCN3C=NC=C3)C=CC=2)C=C1C(C=1)=CC=CC=1OCC1=CC=CC=C1 VOZWHXUJKAXJQX-UHFFFAOYSA-N 0.000 description 1
- RCZUKUIDKWHZBJ-UHFFFAOYSA-N 7-[3-[[2-(1h-imidazol-5-yl)ethylamino]methyl]phenyl]-5-phenylpyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1=2C(N)=NC=NC=2N(C=2C=C(CNCCC=3N=CNC=3)C=CC=2)C=C1C1=CC=CC=C1 RCZUKUIDKWHZBJ-UHFFFAOYSA-N 0.000 description 1
- ADFRHWQNWYOIMQ-UHFFFAOYSA-N 7-[4-(2-aminoethoxy)phenyl]-5-phenylpyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1=CC(OCCN)=CC=C1N1C2=NC=NC(N)=C2C(C=2C=CC=CC=2)=C1 ADFRHWQNWYOIMQ-UHFFFAOYSA-N 0.000 description 1
- ZFJLGECICICULG-UHFFFAOYSA-N 7-[4-(2-aminoethylsulfinyl)phenyl]-5-phenylpyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1=CC(S(=O)CCN)=CC=C1N1C2=NC=NC(N)=C2C(C=2C=CC=CC=2)=C1 ZFJLGECICICULG-UHFFFAOYSA-N 0.000 description 1
- VCVOJMYMMSXWLG-UHFFFAOYSA-N 7-[4-(2-aminoethylsulfonyl)phenyl]-5-phenylpyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1=CC(S(=O)(=O)CCN)=CC=C1N1C2=NC=NC(N)=C2C(C=2C=CC=CC=2)=C1 VCVOJMYMMSXWLG-UHFFFAOYSA-N 0.000 description 1
- BQCUTGYOGZXZAC-UHFFFAOYSA-N 7-[4-(2-imidazol-1-ylethoxy)phenyl]-5-(3-phenylmethoxyphenyl)pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1=2C(N)=NC=NC=2N(C=2C=CC(OCCN3C=NC=C3)=CC=2)C=C1C(C=1)=CC=CC=1OCC1=CC=CC=C1 BQCUTGYOGZXZAC-UHFFFAOYSA-N 0.000 description 1
- WGXIJUCRBGTGJO-UHFFFAOYSA-N 7-[4-(2-imidazol-1-ylethoxy)phenyl]-5-(4-phenylmethoxyphenyl)pyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1=2C(N)=NC=NC=2N(C=2C=CC(OCCN3C=NC=C3)=CC=2)C=C1C(C=C1)=CC=C1OCC1=CC=CC=C1 WGXIJUCRBGTGJO-UHFFFAOYSA-N 0.000 description 1
- QEYBRQBWQDILSG-UHFFFAOYSA-N 7-[4-[[2-(1h-imidazol-5-yl)ethylamino]methyl]phenyl]-5-phenylpyrrolo[2,3-d]pyrimidin-4-amine Chemical compound C1=2C(N)=NC=NC=2N(C=2C=CC(CNCCC=3N=CNC=3)=CC=2)C=C1C1=CC=CC=C1 QEYBRQBWQDILSG-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- CYJRNFFLTBEQSQ-UHFFFAOYSA-N 8-(3-methyl-1-benzothiophen-5-yl)-N-(4-methylsulfonylpyridin-3-yl)quinoxalin-6-amine Chemical compound CS(=O)(=O)C1=C(C=NC=C1)NC=1C=C2N=CC=NC2=C(C=1)C=1C=CC2=C(C(=CS2)C)C=1 CYJRNFFLTBEQSQ-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 206010027654 Allergic conditions Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- BMFMQGXDDJALKQ-BYPYZUCNSA-N Argininic acid Chemical compound NC(N)=NCCC[C@H](O)C(O)=O BMFMQGXDDJALKQ-BYPYZUCNSA-N 0.000 description 1
- 208000006386 Bone Resorption Diseases 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- RMBBSOLAGVEUSI-UHFFFAOYSA-H Calcium arsenate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-][As]([O-])([O-])=O.[O-][As]([O-])([O-])=O RMBBSOLAGVEUSI-UHFFFAOYSA-H 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 229910021590 Copper(II) bromide Inorganic materials 0.000 description 1
- AAWZDTNXLSGCEK-UHFFFAOYSA-N Cordycepinsaeure Natural products OC1CC(O)(C(O)=O)CC(O)C1O AAWZDTNXLSGCEK-UHFFFAOYSA-N 0.000 description 1
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical group O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N DMSO Substances CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 239000005947 Dimethoate Substances 0.000 description 1
- 102100022404 E3 ubiquitin-protein ligase Midline-1 Human genes 0.000 description 1
- 101710102210 E3 ubiquitin-protein ligase Midline-1 Proteins 0.000 description 1
- 102000001301 EGF receptor Human genes 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 208000037147 Hypercalcaemia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 238000005684 Liebig rearrangement reaction Methods 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 241001072332 Monia Species 0.000 description 1
- AYCPARAPKDAOEN-LJQANCHMSA-N N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(2-methyl-4-thieno[3,2-d]pyrimidinyl)amino]-1,4-dihydropyrrolo[3,4-c]pyrazole-5-carboxamide Chemical compound C1([C@H](NC(=O)N2C(C=3NN=C(NC=4C=5SC=CC=5N=C(C)N=4)C=3C2)(C)C)CN(C)C)=CC=CC=C1 AYCPARAPKDAOEN-LJQANCHMSA-N 0.000 description 1
- UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 208000003788 Neoplasm Micrometastasis Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 208000010191 Osteitis Deformans Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 208000027868 Paget disease Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- AAWZDTNXLSGCEK-ZHQZDSKASA-N Quinic acid Natural products O[C@H]1CC(O)(C(O)=O)C[C@H](O)C1O AAWZDTNXLSGCEK-ZHQZDSKASA-N 0.000 description 1
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 229910021607 Silver chloride Inorganic materials 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229910052776 Thorium Inorganic materials 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 235000018936 Vitellaria paradoxa Nutrition 0.000 description 1
- 108010046882 ZAP-70 Protein-Tyrosine Kinase Proteins 0.000 description 1
- 102000007624 ZAP-70 Protein-Tyrosine Kinase Human genes 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- LXRZVMYMQHNYJB-UNXOBOICSA-N [(1R,2S,4R)-4-[[5-[4-[(1R)-7-chloro-1,2,3,4-tetrahydroisoquinolin-1-yl]-5-methylthiophene-2-carbonyl]pyrimidin-4-yl]amino]-2-hydroxycyclopentyl]methyl sulfamate Chemical compound CC1=C(C=C(S1)C(=O)C1=C(N[C@H]2C[C@H](O)[C@@H](COS(N)(=O)=O)C2)N=CN=C1)[C@@H]1NCCC2=C1C=C(Cl)C=C2 LXRZVMYMQHNYJB-UNXOBOICSA-N 0.000 description 1
- SMEGJBVQLJJKKX-HOTMZDKISA-N [(2R,3S,4S,5R,6R)-5-acetyloxy-3,4,6-trihydroxyoxan-2-yl]methyl acetate Chemical compound CC(=O)OC[C@@H]1[C@H]([C@@H]([C@H]([C@@H](O1)O)OC(=O)C)O)O SMEGJBVQLJJKKX-HOTMZDKISA-N 0.000 description 1
- CZOUTEDNZRYTGU-UHFFFAOYSA-N [2-(4-amino-5-phenylpyrrolo[2,3-d]pyrimidin-7-yl)phenyl]methanol Chemical compound C1=2C(N)=NC=NC=2N(C=2C(=CC=CC=2)CO)C=C1C1=CC=CC=C1 CZOUTEDNZRYTGU-UHFFFAOYSA-N 0.000 description 1
- YHRRFPHKXXYHDL-UHFFFAOYSA-N [3-(4-amino-5-phenylpyrrolo[2,3-d]pyrimidin-7-yl)phenyl]methanol Chemical compound C1=2C(N)=NC=NC=2N(C=2C=C(CO)C=CC=2)C=C1C1=CC=CC=C1 YHRRFPHKXXYHDL-UHFFFAOYSA-N 0.000 description 1
- ZEIDAVRRZPXVHY-UHFFFAOYSA-N [3-[4-amino-5-(3,4-dimethoxyphenyl)pyrrolo[2,3-d]pyrimidin-7-yl]phenyl]methanol Chemical compound C1=C(OC)C(OC)=CC=C1C(C1=C(N)N=CN=C11)=CN1C1=CC=CC(CO)=C1 ZEIDAVRRZPXVHY-UHFFFAOYSA-N 0.000 description 1
- DHKJMXHLKKNTKJ-UHFFFAOYSA-N [3-[4-amino-5-(3-methoxyphenyl)pyrrolo[2,3-d]pyrimidin-7-yl]phenyl]methanol Chemical compound COC1=CC=CC(C=2C3=C(N)N=CN=C3N(C=3C=C(CO)C=CC=3)C=2)=C1 DHKJMXHLKKNTKJ-UHFFFAOYSA-N 0.000 description 1
- QEKCMFKWDZHOOD-UHFFFAOYSA-N [4-(4-amino-5-phenylpyrrolo[2,3-d]pyrimidin-7-yl)phenyl]methanol Chemical compound C1=2C(N)=NC=NC=2N(C=2C=CC(CO)=CC=2)C=C1C1=CC=CC=C1 QEKCMFKWDZHOOD-UHFFFAOYSA-N 0.000 description 1
- LJLFPIXLZMJXRW-UHFFFAOYSA-N [4-(4-amino-7-phenylpyrrolo[2,3-d]pyrimidin-5-yl)phenyl]methanol Chemical compound C1=2C(N)=NC=NC=2N(C=2C=CC=CC=2)C=C1C1=CC=C(CO)C=C1 LJLFPIXLZMJXRW-UHFFFAOYSA-N 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 150000008062 acetophenones Chemical class 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 229940081735 acetylcellulose Drugs 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 125000002905 alkanoylamido group Chemical group 0.000 description 1
- 125000004644 alkyl sulfinyl group Chemical group 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000010640 amide synthesis reaction Methods 0.000 description 1
- 150000001409 amidines Chemical class 0.000 description 1
- IMIDOCRTMDIQIJ-UHFFFAOYSA-N aminocarb Chemical compound CNC(=O)OC1=CC=C(N(C)C)C(C)=C1 IMIDOCRTMDIQIJ-UHFFFAOYSA-N 0.000 description 1
- IMUDHTPIFIBORV-UHFFFAOYSA-N aminoethylpiperazine Chemical compound NCCN1CCNCC1 IMUDHTPIFIBORV-UHFFFAOYSA-N 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 150000008366 benzophenones Chemical group 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 230000024279 bone resorption Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229940103357 calcium arsenate Drugs 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 239000003245 coal Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 150000001879 copper Chemical class 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- MLIREBYILWEBDM-UHFFFAOYSA-N cyanoacetic acid Chemical compound OC(=O)CC#N MLIREBYILWEBDM-UHFFFAOYSA-N 0.000 description 1
- CPPKAGUPTKIMNP-UHFFFAOYSA-N cyanogen fluoride Chemical compound FC#N CPPKAGUPTKIMNP-UHFFFAOYSA-N 0.000 description 1
- 125000004802 cyanophenyl group Chemical group 0.000 description 1
- 229940109275 cyclamate Drugs 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- MKXZASYAUGDDCJ-QNNIAVNKSA-N deudextromethorphan Chemical compound C([C@@H]12)CCC[C@]11CCN(C([2H])([2H])[2H])[C@H]2CC2=CC=C(OC([2H])([2H])[2H])C=C21 MKXZASYAUGDDCJ-QNNIAVNKSA-N 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical class CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- STWBDMPOBAUTIM-UHFFFAOYSA-N ethyl 3-(2-acetylanilino)benzoate Chemical compound CCOC(=O)C1=CC=CC(NC=2C(=CC=CC=2)C(C)=O)=C1 STWBDMPOBAUTIM-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 238000004508 fractional distillation Methods 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000005639 glycero group Chemical group 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 230000002140 halogenating effect Effects 0.000 description 1
- 230000026030 halogenation Effects 0.000 description 1
- 238000005658 halogenation reaction Methods 0.000 description 1
- 125000004970 halomethyl group Chemical group 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000000148 hypercalcaemia Effects 0.000 description 1
- 208000030915 hypercalcemia disease Diseases 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910017053 inorganic salt Inorganic materials 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- YLTGFGDODHXMFB-UHFFFAOYSA-N isoacetovanillone Chemical compound COC1=CC=C(C(C)=O)C=C1O YLTGFGDODHXMFB-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 208000027202 mammary Paget disease Diseases 0.000 description 1
- COTNUBDHGSIOTA-UHFFFAOYSA-N meoh methanol Chemical compound OC.OC COTNUBDHGSIOTA-UHFFFAOYSA-N 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- 229940102396 methyl bromide Drugs 0.000 description 1
- GZUXJHMPEANEGY-UHFFFAOYSA-N methyl bromide Substances BrC GZUXJHMPEANEGY-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N methyl monoether Natural products COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- JVXWBUKIPSYAHU-UHFFFAOYSA-N n'-[[3-(4-amino-5-phenylpyrrolo[2,3-d]pyrimidin-7-yl)phenyl]methyl]ethane-1,2-diamine Chemical compound NCCNCC1=CC=CC(N2C3=NC=NC(N)=C3C(C=3C=CC=CC=3)=C2)=C1 JVXWBUKIPSYAHU-UHFFFAOYSA-N 0.000 description 1
- SENSEZLWHCEJJH-UHFFFAOYSA-N n'-[[4-(4-amino-5-phenylpyrrolo[2,3-d]pyrimidin-7-yl)phenyl]methyl]ethane-1,2-diamine Chemical compound C1=CC(CNCCN)=CC=C1N1C2=NC=NC(N)=C2C(C=2C=CC=CC=2)=C1 SENSEZLWHCEJJH-UHFFFAOYSA-N 0.000 description 1
- PHZDEABCWBMSDT-UHFFFAOYSA-N n,n-dimethylformamide;hexane Chemical compound CN(C)C=O.CCCCCC PHZDEABCWBMSDT-UHFFFAOYSA-N 0.000 description 1
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000007764 o/w emulsion Substances 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 238000009806 oophorectomy Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000001599 osteoclastic effect Effects 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- LCCNCVORNKJIRZ-UHFFFAOYSA-N parathion Chemical compound CCOP(=S)(OCC)OC1=CC=C([N+]([O-])=O)C=C1 LCCNCVORNKJIRZ-UHFFFAOYSA-N 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 229940116317 potato starch Drugs 0.000 description 1
- 235000012015 potatoes Nutrition 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical group CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 238000009938 salting Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- XIIOFHFUYBLOLW-UHFFFAOYSA-N selpercatinib Chemical compound OC(COC=1C=C(C=2N(C=1)N=CC=2C#N)C=1C=NC(=CC=1)N1CC2N(C(C1)C2)CC=1C=NC(=CC=1)OC)(C)C XIIOFHFUYBLOLW-UHFFFAOYSA-N 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- CQLFBEKRDQMJLZ-UHFFFAOYSA-M silver acetate Chemical compound [Ag+].CC([O-])=O CQLFBEKRDQMJLZ-UHFFFAOYSA-M 0.000 description 1
- 229940071536 silver acetate Drugs 0.000 description 1
- HKZLPVFGJNLROG-UHFFFAOYSA-M silver monochloride Chemical compound [Cl-].[Ag+] HKZLPVFGJNLROG-UHFFFAOYSA-M 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- YFGAFXCSLUUJRG-WCCKRBBISA-M sodium;(2s)-2-amino-5-(diaminomethylideneamino)pentanoate Chemical compound [Na+].[O-]C(=O)[C@@H](N)CCCN=C(N)N YFGAFXCSLUUJRG-WCCKRBBISA-M 0.000 description 1
- GGCZERPQGJTIQP-UHFFFAOYSA-N sodium;9,10-dioxoanthracene-2-sulfonic acid Chemical compound [Na+].C1=CC=C2C(=O)C3=CC(S(=O)(=O)O)=CC=C3C(=O)C2=C1 GGCZERPQGJTIQP-UHFFFAOYSA-N 0.000 description 1
- 108700026239 src Genes Proteins 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229960002317 succinimide Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 150000003461 sulfonyl halides Chemical class 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 229910052714 tellurium Inorganic materials 0.000 description 1
- PORWMNRCUJJQNO-UHFFFAOYSA-N tellurium atom Chemical compound [Te] PORWMNRCUJJQNO-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- FQZJYWMRQDKBQN-UHFFFAOYSA-N tricaine methanesulfonate Chemical compound CS([O-])(=O)=O.CCOC(=O)C1=CC=CC([NH3+])=C1 FQZJYWMRQDKBQN-UHFFFAOYSA-N 0.000 description 1
- 229940078499 tricalcium phosphate Drugs 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
- GRGCWBWNLSTIEN-UHFFFAOYSA-N trifluoromethanesulfonyl chloride Chemical compound FC(F)(F)S(Cl)(=O)=O GRGCWBWNLSTIEN-UHFFFAOYSA-N 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Nutrition Science (AREA)
- Transplantation (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyrrole Compounds (AREA)
- Detergent Compositions (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.I式: (式中、 R1はアリールであり; R2は水素、低級アルキル又はハロゲンであり;そして R3、はアリールであるが; 但しR2が水素で、R1がフェニル、4−メチルフェニル、4−メトキシフェニ ル、4−クロロフェニル、4−ブロモフェニル又は4−ヨードフェニルである場 合には、R3はフェニル、4−メトキシフェニル及び4−クロロフェニル以外で ある) の化合物及びその塩。 2.請求項1記載のI式: (式中、 R1は、置換されないかあるいは低級アルキル、ハロ低級アルキル、(ヒドロ キシ又は低級アルカノイルオキシ)−低級アルキル、低級アルコキシ低級アルキ ル、(ヒドロキシ、低級アルコキシ又は低級アルカノイルオキシ)−低級アルコ キシ−低級アルキル、(アミノ、低級アルキルアミノ、ジ低級アルキルアミノ又 は低級アルカノイルアミノ)−低級アルコキシ−低級アルキル、(アミノ又は低 級アルカノイルアミノ)−低級アルキル、低級アルキルアミノ−低級アルキル、 ジ低級アルキルアミノ−低級アルキル、(ピペリジニ ル、ピペラジニル、モルホリニル又はピロリジニル)−低級アルキル、(イミダ ゾリル、トリアゾリル、ピリジル、ピリミジニル又はピロリル)−低級アルキル 、(ヒドロキシ、低級アルコキシ又は低級アルカノイルオキシ)−低級アルキル アミノ−低級アルキル、(アミノ、低級アルキルアミノ、ジ低級アルキルアミノ 又は低級アルカノイルアミノ)−低級アルキルアミノ−低級アルキル、(ピペリ ジニル、ピペラジニル、モルホリニル又はピロリジニル)−低級アルキルアミノ −低級アルキル、(イミダゾリル、トリアゾリル、ピリジル、ピリミジニル又は ピロリル)−低級アルキルアミノ−低級アルキル、メルカプト−低級アルキル、 低級アルキル−(チオ、スルフィニル又はスルホニル)−低級アルキル、(ヒド ロキシ、低級アルコキシ又は低級アルカノイルオキシ)−低級アルキル−(チオ 、スルフィニル又はスルホニル)−低級アルキル、(アミノ、低級アルキルアミ ノ、ジ−低級アルキルアミノ又は低級アルカノイルアミノ)−低級アルキル−( チオ、スルフィニル又はスルホニル)−低級アルキル、カルボキシ−低級アルキ ル、低級アルコキシカルボニル−低級アルキル、アミノカルボニル−低級アルキ ル、N−低級アルキルアミノカルボニル−低級アルキル、N,N−ジ−低級アル キルアミノカルボニル−低級アルキル、ヒドロキシル、低級アルコキシ、低級ア ルカノイルオキシ、C1〜C3アルキレンジオキシ、フェニル−低級アルコキシ、 (ヒドロキシ、低級アルコキシ又は低級アルカノイルオキシ)−低級アルコキシ 、(アミノ又は低級アルカノイルアミノ)−低級アルコキシ、低級アルキルアミ ノ−低級アルコキシ、ジ−低級アルキルアミノ−低級アルコキシ、(ピペリジニ ル、ピペラジニル、モルホリニル又はピロリジニル)−低級アルコキシ、(イミ ダゾリル、トリアゾリル、ピリジル、ピリミジニル又はピロリル)−低級アルコ キシ、(ヒドロキシ、低級アルコキシ 又は低級アルカノイルオキシ)−低級アルキルアミノ−低級アルコキシ、(アミ ノ、低級アルキルアミノ、ジ−低級アルキルアミノ又は低級アルカノイルアミノ )−低級アルキルアミノ−低級アルコキシ、(ピペリジニル、ピペラジニル、モ ルホリニル又はピロリジニル)−低級アルキルアミノ−低級アルコキシ、(イミ ダゾリル、トリアゾリル、ピリジル、ピリミジニル又はピロリル)−低級アルキ ルアミノ−低級アルコキシ、(ヒドロキシ、低級アルコキシ又は低級アルカノイ ルオキシ)−低級アルコキシ−低級アルコキシ、(アミノ、低級アルキルアミノ 、ジ−低級アルキルアミノ又は低級アルカノイルアミノ)−低級アルコキシ−低 級アルコキシ、(ヒドロキシ、低級アルコキシ又は低級アルカノイルオキシ)− 低級アルキル−(チオ、スルフィニル又はスルホニル)−低級アルコキシ、(ア ミノ、低級アルキルアミノ、ジ−低級アルキルアミノ又は低級アルカノイルアミ ノ)−低級アルキル−(チオ、スルフィニル又はスルホニル)−低級アルコキシ 、ヒドロキシスルホニル−低級アルコキシ、カルボキシ−低級アルコキシ、低級 アルコキシカルボニル−低級アルコキシ、アミノカルボニル−低級アルコキシ、 N−低級アルキルアミノカルボニル−低級アルコキシ、N,N−ジ−低級アルキ ルアミノカルボニル−低級アルコキシ、アミノ、低級アルキルアミノ、ジ−低級 アルキルアミノ、低級アルカノイルアミノ、ピペリジニル、ピペラジニル、モル ホリニル又はピロリジニル、イミダゾリル、トリアゾリル、ピリジル、ピリミジ ニル又はピロリル、メルカプト、低級アルキル−(チオ、スルフィニル又はスル ホニル)、(ヒドロキシ、低級アルコキシ又は低級アルカノイルオキシ)−低級 アルキル−(チオ、スルフィニル又はスルホニル)、(アミノ、低級アルキルア ミノ、ジ−低級アルキルアミノ又は低級アルカノイルアミノ)−低級アルキル− (チオ、スルフィニル又はスルホニル) 、(ヒドロキシ、低級アルコキシ又は低級アルカノイルオキシ)−低級アルコキ シ−低級アルキル−(チオ、スルフィニル又はスルホニル)、(アミノ、低級ア ルキルアミノ、ジ−低級アルキルアミノ又は低級アルカノイルアミノ)−低級ア ルコキシ−低級アルキル−(チオ、スルフィニル又はスルホニル)、(ヒドロキ シ、低級アルコキシ又は低級アルカノイルオキシ)−低級アルキルアミノ−低級 アルキル−(チオ、スルフィニル又はスルホニル)、(アミノ、低級アルキルア ミノ、ジ−低級アルキルアミノ又はアルカノイルアミノ)−低級アルキルアミノ −低級アルキル−(チオ、スルフィニル又はスルホニル)、カルボキシ−低級ア ルキルチオ、低級アルコキシカルボニル−低級アルキルチオ、アミノカルボニル −低級アルキルチオ、N−低級アルキルアミノカルボニル−低級アルキルチオ、 N,N−ジ−低級アルキルアミノカルボニル−低級アルキルチオ、ハロゲン、カ ルボキシル、低級アルコキシカルボニル、アミノカルボニル、N−低級アルキル アミノカルボニル、N−〔(ヒドロキシ、低級アルコキシ又は低級アルカノイル オキシ)−低級アルキル〕−アミノカルボニル、N−〔(アミノ、低級アルキル アミノ、ジ−低級アルキルアミノ又は低級アルカノイルアミノ)−低級アルキル 〕−アミノカルボニル、N−〔(ピペリジニル、ピペラジニル、モルホリニル又 はピロリジニル)−低級アルキル〕−アミノカルボニル、N−〔(イミダゾリル 、トリアゾリル、ピリジル、ピリミジニル又はピロリル)−低級アルキル〕−ア ミノカルボニル、N−(ヒドロキシスルホニル−低級アルキル)−アミノカルボ ニル、N,N−ジ−低級アルキルアミノカルボニル、シアノ、アミジノ、ホルム アミジノ及びグアニジノから成る群からの1つ又は2つの置換基により置換され るフェニルであり; R2は水素、低級アルキル又はハロゲンであり;そして R3は、置換されないか、あるいは低級アルキル、ヒドロキシ−低級アルキル 、フェニル、ヒドロキシル、低級アルコキシ、フェニル−低級アルコキシ、C〜 C3アルキレンジオキシ、シアノ及びハロゲンから成る群からの1、2又は3つ の置換基により置換されるフェニルであるが; 但し、R2が水素で、R1がフェニル、4−メチルフェニル、4−メトキシフェ ニル、4−クロロフェニル、4−ブロモフェニル又は4−ヨードフェニルである 場合には、R3はフェニル、4−メトキシフェニル及び4−クロロフェニル以外 のものである) の化合物又はその塩。 3.請求項1記載のI式: (式中、 R1は置換されないかあるいは低級アルキル、ヒドロキシ−低級アルキル、低 級アルカノイルオキシ−低級アルキル、ハロ低級アルキル、アミノ−低級アルキ ル、低級アルキルアミノ−低級アルキル、ジ低級アルキルアミノ−低級アルキル 、(ピペリジニル、ピペラジニル、モルホリニル又はピロリジニル)−低級アル キル、(イミダゾリル、トリアゾリル、ピリジル、ピリミジニル又はピロリル) −低級アルキル、ヒドロキシ−低級アルキルアミノ−低級アルキル、アミノ−低 級アルキルアミノ−低級アルキル、(ピペリジニル、ピペラジニル、モルホリニ ル又はピロリジニル)−低級アルキルアミノ−低級アルキル、(イミダゾリル、 トリアゾリル、ピリジル、ピリミジニル又はピロリル)−低級アルキルアミノ− 低級アルキル、メルカプト−低級アルキル、低級アルキル−(チオ、スルフィニ ル又はスルホニル)−低級アルキル、ヒドロキシ−低級アルキル−(チオ、スル フィニル又はスルホニル)−低級アルキル、アミノ−低級アルキル−(チオ、ス ルフィニル又はスルホニル)−低級アル キル、ヒドロキシル、低級アルコキシ、C1〜C3アルキレンジオキシ、フェニル −低級アルコキシ、ヒドロキシ−低級アルコキシ、低級アルコキシ−低級アルコ キシ、低級アルカノイルオキシ−低級アルコキシ、アミノ−低級アルコキシ、低 級アルキルアミノ−低級アルコキシ、ジ−低級アルキルアミノ−低級アルコキシ 、(ピペリジニル、ピペラジニル、モルホリニル又はピロリジニル)−低級アル コキシ、(イミダゾリル、トリアゾリル、ピリジル、ピリミジニル又はピロリル )−低級アルコキシ、ヒドロキシ−低級アルキルアミノ−低級アルコキシ、アミ ノ−低アルキルアミノ−低級アルコキシ、(ピペリジニル、ピペラジニル、モル ホリニル又はピロリジニル)−低級アルキルアミノ−低級アルコキシ、(イミダ ゾリル、トリアゾリル、ピリジル、ピリミジニル又はピロリル)−低級アルキル アミノ−低級アルコキシ、ヒドロキシスルホニル−低級アルコキシ、アミノ、ピ ペリジニル、ピペラジニル、モルホリニル又はピロリジニル、イミダゾリル、ト リアゾリル、ピリジル、ピリミジニル、ピロリル、メルカプト、低級アルキル− (チオ、スルフィニル又はスルホニル)、ヒドロキシ−低級アルキル−(チオ、 スルフィニル又はスルホニル)、アミノ−低級アルキル−(チオ、スルフィニル 又はスルホニル)、ハロゲン、カルボキシル、低級アルコキシカルボニル、アミ ノカルボニル、N−低級アルキルアミノカルボニル、N−〔(ヒドロキシ−低級 アルキル〕−アミノカルボニル、N−(アミノ−低級アルキル)−アミノカルボ ニル、N−〔(ピペリジニル、ピペラジニル、モルホリニル又はピロリジニル) −低級アルキル〕−アミノカルボニル、N−〔(イミダゾリル、トリアゾリル、 ピリジル、ピリミジニル又はピロリル)−低級アルキル〕−アミノカルボニル、 N−(ヒドロキシスルホニル−低級アルキル)−アミノカルボニル、N,N−ジ −低級アルキルアミノカルボニル及び シアノから成る群からの置換基により置換されるフェニルであり; R2は水素、低級アルキル又はハロゲンであり;そして R3は、置換されないか、あるいは低級アルキル、ヒドロキシ−低級アルキル 、フェニル、ヒドロキシル、低級アルコキシ、フェニル−低級アルコキシ、C〜 C3アルキレンジオキシ、シアノ及びハロゲンから成る群からの1、2又は3つ の置換基により置換されるフェニルであるが; 但し、R2が水素で、R1がフェニル、4−メチルフェニル、4−メトキシフェ ニル、4−クロロフェニル、4−ブロモフェニル又は4−ヨードフェニルである 場合には、R3はフェニル、4−メトキシフェニル及び4−クロロフェニル以外 のものである) の化合物、又は製薬上許容可能なその塩。 4.請求項1記載のI式: (式中、 R1は置換されないかあるいは低級アルキル、ヒドロキシ−低級アルキル、ハ ロ低級アルキル、アミノ−低級アルキル、低級アルキルアミノ−低級アルキル、 ジ低級アルキルアミノ−低級アルキル、(ピリミジニル、ピペラジニル又はモル ホリニル)−低級アルキル、(イミダゾリル、トリアゾリル、ピリジル、ピリミ ジニル又はピロリル)−低級アルキル、ヒドロキシ−低級アルキルアミノ−低級 アルキル、アミノ−低級アルキルアミノ−低級アルキル、(ピリミジニル、ピペ ラジニル又はモルホリニル)−低級アルキルアミノ−低級アルキル、(イミダゾ リル、トリアゾリル、ピリジル、ピリミジニル又はピロリル)−低級アルキルア ミノ−低級アルキル、メルカプト−低級アルキル、低級アルキル−(チオ、スル フィニル又はスルホニル)−低級アルキル、ヒドロキシ−低級アルキル−(チオ 、スルフィニル又はスルホニル)−低級アルキル、アミノ−低級ア ルキル−(チオ、スルフィニル又はスルホニル)−低級アルキル、ヒドロキシル 、低級アルコキシ、C1〜C3アルキレンジオキシ、フェニル−低級アルコキシ、 ヒドロキシ−低級アルコキシ、アミノ−低級アルコキシ、低級アルキルアミノ− 低級アルコキシ、ジ−低級アルキルアミノ−低級アルコキシ、(ピリミジニル、 ピペラジニル又はモルホリニル)−低級アルコキシ、(イミダゾリル、トリアゾ リル、ピリジル、ピリミジニル又はピロリル)−低級アルコキシ、ヒドロキシ− 低級アルキルアミノ−低級アルコキシ、アミノ−低級アルキルアミノ−低級アル コキシ、(ピリミジニル、ピペラジニル又はモルホリニル)−低級アルキルアミ ノ−低級アルコキシ、(イミダゾリル、トリアゾリル、ピリジル、ピリミジニル 又はピロリル)−低級アルキルアミノ−低級アルコキシ、ヒドロキシスルホニル −低級アルコキシ、アミノ、ピリミジニル、ピペラジニル、モルホリニル、イミ ダゾリル、トリアゾリル、ピリジル、ピロリル、メルカプト、低級アルキル−( チオ、スルフィニル又はスルホニル)、ヒドロキシ−低級アルキル−(チオ、ス ルフィニル又はスルホニル)、アミノ−低級アルキル−(チオ、スルフィニル又 はスルホニル)、ハロゲン、カルボキシル、低級アルコキシカルボニル、アミノ カルボニル、N−低級アルキルアミノカルボニル、N−〔(ヒドロキシ−低級ア ルキル〕−アミノカルボニル、N−(アミノ−低級アルキル)−アミノカルボニ ル、N−〔(ピリミジニル、ピペラジニル又はモルホリニル)−低級アルキル〕 −アミノカルボニル、N−〔(イミダゾリル、トリアゾリル、ピリジル又はピロ リル)−低級アルキル〕−アミノカルボニル、N−(ヒドロキシスルホニル−低 級アルキル)−アミノカルボニル、N,N−ジ−低級アルキルアミノカルボニル 及びシアノから成る群からの置換基により置換されるフェニルであり; R2は水素、低級アルキル又はハロゲンであり;そして R3、は、置換されないか、あるいは低級アルキル、フェニル、ヒドロキシル 、低級アルコキシ、フェニル−低級アルコキシ、C〜C3アルキレンジオキシ、 シアノ及びハロゲンから成る群からの置換基により置換されるフェニルであるが ; 但し、R2が水素で、R1がフェニル、4−メチルフェニル、4−メトキシフェ ニル、4−クロロフェニル、4−ブロモフェニル又は4−ヨードフェニルである 場合には、R3はフェニル、4−メトキシフェニル及び4−クロロフェニル以外 のものである) の化合物又は製薬上許容可能なその塩。 5.請求項1記載のN−(2−ヒドロキシエチル)−3−(5−フェニル−4 −アミノピロロ〔2,3−d〕ピリミジン−7−イル)ベンズアミド又は製薬上 許容可能なその塩。 6.タンパク質チロシンキナーゼpp60c-srcの活性の阻害に反応する疾患 の治療のための薬剤の調製のためののI式: (式中、 R1はアリールであり; R2は水素、低級アルキル又はハロゲンであり;そして R3はアリールである) の化合物又は製薬上許容可能なその塩の使用。 7.R1が置換されないか又は低級アルキル、ハロ低級アルキル、(ヒドロキ シ又は低級アルカノイルオキシ)−低級アルキル、低 級アルコキシ低級アルキル、(ヒドロキシ、低級アルコキシ又は低級アルカノイ ルオキシ)−低級アルコキシ−低級アルキル、(アミノ、低級アルキルアミノ、 ジ低級アルキルアミノ又は低級アルカノイルアミノ)−低級アルコキシ−低級ア ルキル、(アミノ又は低級アルカノイルアミノ)−低級アルキル、低級アルキル アミノ−低級アルキル、ジ低級アルキルアミノ−低級アルキル、(ピペリジニル 、ピペラジニル、モルホリニル又はピロリジニル)−低級アルキル、(イミダゾ リル、トリアゾリル、ピリジル、ピリミジニル又はピロリル)−低級アルキル、 (ヒドロキシ、低級アルコキシ又は低級アルカノイルオキシ)−低級アルキルア ミノ−低級アルキル、(アミノ、低級アルキルアミノ、ジ低級アルキルアミノ又 は低級アルカノイルアミノ)−低級アルキルアミノ−低級アルキル、(ピペリジ ニル、ピペラジニル、モルホリニル又はピロリジニル)−低級アルキルアミノ− 低級アルキル、(イミダゾリル、トリアゾリル、ピリジル、ピリミジニル又はピ ロリル)−低級アルキルアミノ−低級アルキル;メルカプト−低級アルキル、低 級アルキル−(チオ、スルフィニル又はスルフォニル)−低級アルキル、(ヒド ロキシ、低級アルコキシ又は低級アルカノイルオキシ)−低級アルキル−(チオ 、スルフィニル又はスルフォニル)−低級アルキル、(アミノ、低級アルキルア ミノ、ジ低級アルキルアミノ又は低級アルカノイルアミノ)−低級アルキル−( チオ、スルフィニル又はスルフォニル)−低級アルキル、カルボキシ−低級アル キル、低級アルコキシカルボニル−低級アルキル、アミノカルボニル−低級アル キル、N−低級アルキルアミノカルボニル−低級アルキル、N,N−ジ−低級ア ルキルアミノカルボニル−低級アルキル、ヒドロキシル、低級アルコキシ、低級 アルカノイルオキシ、C1〜C3アルキレンジオキシ、フェニル−低級アルコキシ 、(ヒドロキシ、低級アルコキシ又は 低級アルカノイルオキシ)−低級アルコキシ、(アミノ又は低級アルカノイルア ミノ)−低級アルコキシ、低級アルキルアミノ−低級アルコキシ、ジ−低級アル キルアミノ−低級アルコキシ、(ピペリジニル、ピペラジニル、モルホリニル又 はピロリジニル)−低級アルコキシ、(イミダゾリル、トリアゾリル、ピリジル 、ピリミジニル又はピロリル)−低級アルコキシ;(ヒドロキシ、低級アルコキ シ又は低級アルカノイルオキシ)−低級アルキルアミノ−低級アルコキシ、(ア ミノ、低級アルキルアミノ、ジ−低級アルキルアミノ又は低級アルカノイルアミ ノ)−低級アルキルアミノ−低級アルコキシ、(ピペリジニル、ピペラジニル、 モルホリニル又はピロリジニル)−低級アルキルアミノ−低級アルコキシ、(イ ミダゾリル、トリアゾリル、ピリジル、ピリミジニル又はピロリル)−低級アル キルアミノ−低級アルコキシ;(ヒドロキシ、低級アルコキシ又は低級アルカノ イルオキシ)−低級アルコキシ−低級アルコキシ、(アミノ、低級アルキルアミ ノ、ジ−低級アルキルアミノ又は低級アルカノイルアミノ)−低級アルコキシ− 低級アルコキシ、(ヒドロキシ、低級アルコキシ又は低級アルカノイルオキシ) −低級アルキル−(チオ、スルフィニル又はスルホニル)−低級アルコキシ、( アミノ、低級アルキルアミノ、ジ−低級アルキルアミノ又は低級アルカノイルア ミノ)−低級アルキル−(チオ、スルフィニル又はスルホニル)−低級アルコキ シ、ヒドロキシスルホニル−低級アルコキシ、カルボキシ−低級アルコキシ、低 級アルコキシカルボニル−低級アルコキシ、アミノカルボニル−低級アルコキシ 、N−低級アルキルアミノカルボニル−低級アルコキシ、N,N−ジ−低級アル キルアミノカルボニル−低級アルコキシ、アミノ、低級アルキルアミノ、ジ−低 級アルキルアミノ、低級アルカノイルアミノ、ピペリジニル、ピペラジニル、モ ルホリニル又はピロリジニル、イミダゾ リル、トリアゾリル、ピリジル、ピリミジニル又はピロリル;メルカプト、低級 アルキル−(チオ、スルフィニル又はスルホニル)、(ヒドロキシ、低級アルコ キシ又は低級アルカノイルオキシ)−低級アルキル−(チオ、スルフィニル又は スルホニル)、(アミノ、低級アルキルアミノ、ジ−低級アルキルアミノ又は低 級アルカノイルアミノ)−低級アルキル−(チオ、スルフィニル又はスルホニル )、(ヒドロキシ、低級アルコキシ又は低級アルカノイルオキシ)−低級アルコ キシ−低級アルキル−(チオ、スルフィニル又はスルホニル)、(アミノ、低級 アルキルアミノ、ジ−低級アルキルアミノ又は低級アルカノイルアミノ)−低級 アルコキシ−低級アルキル−(チオ、スルフィニル又はスルホニル)、(ヒドロ キシ、低級アルコキシ又は低級アルカノイルオキシ)−低級アルキルアミノ−低 級アルキル−(チオ、スルフィニル又はスルホニル)、(アミノ、低級アルキル アミノ、ジ−低級アルキルアミノ又はアルカノイルアミノ)−低級アルキルアミ ノ−低級アルキル−(チオ、スルフィニル又はスルホニル)、カルボキシ−低級 アルキルチオ、低級アルコキシカルボニル−低級アルキルチオ、アミノカルボニ ル−低級アルキルチオ、N−低級アルキルアミノカルボニル−低級アルキルチオ 、N,N−ジ−低級アルキルアミノカルボニル−低級アルキルチオ、ハロゲン、 カルボキシル、低級アルコキシカルボニル、アミノカルボニル、N−低級アルキ ルアミノカルボニル、N−〔(ヒドロキシ、低級アルコキシ又は低級アルカノイ ルオキシ)−低級アルキル〕−アミノカルボニル、N−〔(アミノ、低級アルキ ルアミノ、ジ−低級アルキルアミノ又は低級アルカノイルアミノ)−低級アルキ ル〕−アミノカルボニル、N−〔(ピペリジニル、ピペラジニル、モルホリニル 又はピロリジニル)−低級アルキル〕−アミノカルボニル、N−〔(イミダゾリ ル、トリアゾリル、ピリジル、ピリミジ ニル又はピロリル)−低級アルキル〕−アミノカルボニル;N−(ヒドロキシス ルホニル−低級アルキル)−アミノカルボニル、N,N−ジ−低級アルキルアミ ノカルボニル、シアノ、アミジノ、ホルムアミジノ及びグアニジノから成る群か らの1つ又は2つの置換基により置換されるフェニルであり; R2が水素、低級アルキル又はハロゲンであり;そして R3が置換されないか、又は低級アルキル、ヒドロキシ−低級アルキル、フェ ニル、ヒドロキシル、低級アルコキシ、フェニル−低級アルコキシ、C〜C3ア ルキレンジオキシ、シアノ及びハロゲンから成る群からの1、2又は3個の置換 基により置換されるフェニルである) の化合物又は製薬上許容可能なその塩が用いられる請求項6記載の使用。 8.I式(式中、R1がフェニル、4−メトキシフェニル、4−クロロフェニ ル、4−ブロモフェニル又は4−ヨードフェニルであり、R2が水素であり、R3 がフェニル、4−メトキシフェニル又は4−クロロフェニルである)の化合物又 は製薬上許容可能なその塩が用いられることを特徴とする請求項6記載の使用。 9.請求項1〜5のいずれかに記載の化合物及び少なくとも1つの製薬上許容 可能な担体を含有する薬理組成物。 10.動物又はヒトの身体の治療的処置のための方法に用いるための請求項1 〜5のいずれかに記載の化合物。 11.タンパク質チロシンキナーゼpp60c-srcの活性の阻害に反応する疾 患の治療に用いるための請求項1〜5のいずれかに記載の化合物。 12.薬理組成物の製造のための請求項1〜5のいずれかに記載の化合物の使 用。 13.タンパク質チロシンキナーゼpp60c-srcの活性の阻害に反応する疾 患の治療のための薬理組成物の製造のための請求項1〜5のいずれかに記載の化 合物の使用。 14.(a)II式: の化合物にピリミジン環の合成を伴う閉環反応を施すか、又は (b)III式: の化合物にピリミジン環の合成を伴う閉環反応を施すか、又は (c)IV式: の化合物を、予備的活性化後に所望により、アミン化試薬と反応させ、 所望により、I式の化合物をI式の別の化合物に変換するか、及び/又は所望 により、その結果生じる塩を遊離化合物又は別の塩に 変換するか、及び/又は所望により、その結果生じる塩生成特性を有するI式の 遊離化合物を塩に変換する請求項1記載のI式の化合物の製造方法。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH295394 | 1994-09-29 | ||
| CH2953/94-3 | 1994-09-29 | ||
| PCT/EP1995/003536 WO1996010028A1 (en) | 1994-09-29 | 1995-09-08 | PYRROLO[2,3-d]PYRIMIDINES AND THEIR USE |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH10506624A true JPH10506624A (ja) | 1998-06-30 |
| JP4145955B2 JP4145955B2 (ja) | 2008-09-03 |
Family
ID=4245363
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP51131296A Expired - Fee Related JP4145955B2 (ja) | 1994-09-29 | 1995-09-08 | ピロロ〔2,3−d〕ピリミジン及びその使用 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US5869485A (ja) |
| EP (1) | EP0783505B1 (ja) |
| JP (1) | JP4145955B2 (ja) |
| KR (1) | KR970706288A (ja) |
| CN (1) | CN1046731C (ja) |
| AT (1) | ATE199553T1 (ja) |
| AU (1) | AU694801B2 (ja) |
| BR (1) | BR9509048A (ja) |
| CA (1) | CA2200210A1 (ja) |
| DE (1) | DE69520282T2 (ja) |
| DK (1) | DK0783505T3 (ja) |
| ES (1) | ES2157344T3 (ja) |
| FI (1) | FI112867B (ja) |
| GR (1) | GR3035996T3 (ja) |
| HU (1) | HU222181B1 (ja) |
| MX (1) | MX9702307A (ja) |
| NO (1) | NO308108B1 (ja) |
| NZ (1) | NZ293249A (ja) |
| PT (1) | PT783505E (ja) |
| WO (1) | WO1996010028A1 (ja) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005502643A (ja) * | 2001-08-10 | 2005-01-27 | ノバルティス アクチエンゲゼルシャフト | 白血病処置のための単独またはsti571と組み合せたc−srcインヒビターの使用 |
| JP2009522284A (ja) * | 2005-12-29 | 2009-06-11 | アボット・ラボラトリーズ | タンパク質キナーゼ阻害薬 |
| JP2012505916A (ja) * | 2008-10-16 | 2012-03-08 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 融合環ヘテロアリールキナーゼ阻害剤 |
| US9321772B2 (en) | 2011-09-02 | 2016-04-26 | The Regents Of The University Of California | Substituted pyrazolo[3,4-D]pyrimidines and uses thereof |
| US10131668B2 (en) | 2012-09-26 | 2018-11-20 | The Regents Of The University Of California | Substituted imidazo[1,5-a]pYRAZINES for modulation of IRE1 |
| JP2022553376A (ja) * | 2019-10-25 | 2022-12-22 | アクセント・セラピューティクス・インコーポレイテッド | Mettl3モジュレーター |
Families Citing this family (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0682027B1 (de) * | 1994-05-03 | 1997-10-15 | Novartis AG | Pyrrolopyrimidinderivate mit antiproliferativer Wirkung |
| MX9800215A (es) * | 1995-07-06 | 1998-03-31 | Novartis Ag | Pirrolopirimidas y procesos para su preparacion. |
| AU3176297A (en) * | 1996-06-25 | 1998-01-14 | Novartis Ag | Substituted 7-amino-pyrrolo{3,2-d}pyrimidines and the use thereof |
| AU3461697A (en) * | 1996-07-19 | 1998-02-10 | Takeda Chemical Industries Ltd. | Heterocyclic compounds, their production and use |
| JP4056589B2 (ja) * | 1996-07-19 | 2008-03-05 | 武田薬品工業株式会社 | 複素環化合物、その製造法および用途 |
| WO1998007726A1 (en) | 1996-08-23 | 1998-02-26 | Novartis Ag | Substituted pyrrolopyrimidines and processes for their preparation |
| US6251911B1 (en) | 1996-10-02 | 2001-06-26 | Novartis Ag | Pyrimidine derivatives and processes for the preparation thereof |
| GB9704948D0 (en) | 1997-03-11 | 1997-04-30 | Knoll Ag | Therapeutic agents |
| DK0970084T3 (da) * | 1997-03-19 | 2003-09-29 | Abbott Gmbh & Co Kg | Pyrrolo[2,3-d]pyrimidiner og deres anvendelse som inhibitorer for tyrosinkinase |
| US7863444B2 (en) | 1997-03-19 | 2011-01-04 | Abbott Laboratories | 4-aminopyrrolopyrimidines as kinase inhibitors |
| ID24300A (id) * | 1997-08-05 | 2000-07-13 | Pfizer Prod Inc | 4-AMINOPIROL(3,2-d)PIRIMIDIN SEBAGAI ANTAGONIS-ANTAGONIS RESEPTOR NEUROPEPTIDA Y |
| YU76100A (sh) * | 1998-06-02 | 2003-12-31 | Osi Pharmaceuticals Inc. | Pirolo(2,3-d) pirimidin preparati i njihova primena |
| CA2344249A1 (en) * | 1998-09-18 | 2000-03-30 | Basf Aktiengesellschaft | Pyrrolopyrimidines as protein kinase inhibitors |
| US6713474B2 (en) | 1998-09-18 | 2004-03-30 | Abbott Gmbh & Co. Kg | Pyrrolopyrimidines as therapeutic agents |
| US7125875B2 (en) | 1999-04-15 | 2006-10-24 | Bristol-Myers Squibb Company | Cyclic protein tyrosine kinase inhibitors |
| CA2385747A1 (en) | 1999-09-17 | 2001-03-22 | Gavin C. Hirst | Pyrazolopyrimidines as therapeutic agents |
| US7071199B1 (en) | 1999-09-17 | 2006-07-04 | Abbott Gmbh & Cco. Kg | Kinase inhibitors as therapeutic agents |
| WO2001072751A1 (en) * | 2000-03-29 | 2001-10-04 | Knoll Gesellschaft Mit Beschraenkter Haftung | Pyrrolopyrimidines as tyrosine kinase inhibitors |
| US6770652B2 (en) * | 2001-10-18 | 2004-08-03 | Duquesne University Of The Holy Ghost | Multiple acting anti-angiogenic and cytotoxic compounds and methods for using the same |
| DE10163991A1 (de) * | 2001-12-24 | 2003-07-03 | Merck Patent Gmbh | Pyrrolo-pyrimidine |
| GB0206215D0 (en) | 2002-03-15 | 2002-05-01 | Novartis Ag | Organic compounds |
| GB0226370D0 (en) * | 2002-11-12 | 2002-12-18 | Novartis Ag | Organic compounds |
| US7157460B2 (en) * | 2003-02-20 | 2007-01-02 | Sugen Inc. | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors |
| JP2007520559A (ja) * | 2004-02-03 | 2007-07-26 | アボット・ラボラトリーズ | 治療薬としてのアミノベンゾオキサゾール類 |
| GB0512324D0 (en) | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
| EP2385053B1 (en) * | 2005-11-17 | 2013-10-02 | OSI Pharmaceuticals, Inc. | Intermediates for the preparation of fused bicyclic mTOR inhibitors |
| US7659274B2 (en) * | 2006-01-25 | 2010-02-09 | Osi Pharmaceuticals, Inc. | Unsaturated mTOR inhibitors |
| WO2009117482A1 (en) * | 2008-03-19 | 2009-09-24 | Osi Pharmaceuticals, Inc | Mtor inhibitor salt forms |
| WO2010066629A2 (en) * | 2008-12-09 | 2010-06-17 | F. Hoffmann-La Roche Ag | Novel azaindoles |
| WO2011029915A1 (en) | 2009-09-10 | 2011-03-17 | Novartis Ag | Ether derivatives of bicyclic heteroaryls |
| WO2011064211A1 (en) | 2009-11-25 | 2011-06-03 | Novartis Ag | Benzene-fused 6-membered oxygen-containing heterocyclic derivatives of bicyclic heteroaryls |
| CN102947274A (zh) | 2010-06-17 | 2013-02-27 | 诺瓦提斯公司 | 联苯基取代的1,3-二氢-苯并咪唑-2-亚基胺衍生物 |
| WO2011157793A1 (en) | 2010-06-17 | 2011-12-22 | Novartis Ag | Piperidinyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives |
| JP2014507465A (ja) | 2011-03-08 | 2014-03-27 | ノバルティス アーゲー | フルオロフェニル二環式ヘテロアリール化合物 |
| BR112013023050A8 (pt) | 2011-03-09 | 2018-09-25 | G Pestell Richard | antagonista de ccr5, método para determinar se um indivíduo humano tendo câncer de próstata está sofrendo de ou sob o risco de desenvolver metástase, para identificar um antagonista de ccr5, método para determinar se um indivíduo humano tendo câncer de próstata está sofrendo de ou sob o risco de desenvolver metástase, para identificar um composto candidato, para produzir in vitro células epiteliais primárias, para diagnosticar câncer de próstata, para selecionar um tratamento para um indivíduo tendo um câncer/tumor de próstata, linhagem de célula, e, modelo animal |
| AU2013262977A1 (en) | 2012-05-14 | 2015-01-22 | Prostagene, Llc | Using modulators of CCR5 for treating cancer |
| WO2014145576A2 (en) | 2013-03-15 | 2014-09-18 | Northwestern University | Substituted pyrrolo(2,3-d)pyrimidines for the treatment of cancer |
| US11920164B2 (en) | 2014-07-30 | 2024-03-05 | Yeda Research And Development Co. Ltd. | Media for culturing naive human pluripotent stem cells |
| EP3334430B1 (en) * | 2015-08-13 | 2025-02-26 | San Diego State University Research Foundation | Atropisomerism for increased kinase inhibitor selectivity |
| US10722484B2 (en) | 2016-03-09 | 2020-07-28 | K-Gen, Inc. | Methods of cancer treatment |
| JP7021356B2 (ja) | 2017-12-21 | 2022-02-16 | ヘフェイ インスティテューツ オブ フィジカル サイエンス, チャイニーズ アカデミー オブ サイエンシーズ | ピリミジン誘導体系キナーゼ阻害剤類 |
| WO2020113094A1 (en) | 2018-11-30 | 2020-06-04 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
| WO2020152686A1 (en) | 2019-01-23 | 2020-07-30 | Yeda Research And Development Co. Ltd. | Culture media for pluripotent stem cells |
| WO2021097256A1 (en) | 2019-11-14 | 2021-05-20 | Cohbar, Inc. | Cxcr4 antagonist peptides |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU661533B2 (en) * | 1992-01-20 | 1995-07-27 | Astrazeneca Ab | Quinazoline derivatives |
| GB9314884D0 (en) * | 1993-07-19 | 1993-09-01 | Zeneca Ltd | Tricyclic derivatives |
| IL112249A (en) * | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
| EP0682027B1 (de) * | 1994-05-03 | 1997-10-15 | Novartis AG | Pyrrolopyrimidinderivate mit antiproliferativer Wirkung |
-
1995
- 1995-09-08 JP JP51131296A patent/JP4145955B2/ja not_active Expired - Fee Related
- 1995-09-08 US US08/793,313 patent/US5869485A/en not_active Expired - Lifetime
- 1995-09-08 KR KR1019970702044A patent/KR970706288A/ko not_active Abandoned
- 1995-09-08 WO PCT/EP1995/003536 patent/WO1996010028A1/en not_active Ceased
- 1995-09-08 CA CA002200210A patent/CA2200210A1/en not_active Abandoned
- 1995-09-08 HU HU9701333A patent/HU222181B1/hu not_active IP Right Cessation
- 1995-09-08 BR BR9509048A patent/BR9509048A/pt not_active IP Right Cessation
- 1995-09-08 AU AU35643/95A patent/AU694801B2/en not_active Ceased
- 1995-09-08 DK DK95932693T patent/DK0783505T3/da active
- 1995-09-08 PT PT95932693T patent/PT783505E/pt unknown
- 1995-09-08 NZ NZ293249A patent/NZ293249A/en active IP Right Revival
- 1995-09-08 AT AT95932693T patent/ATE199553T1/de not_active IP Right Cessation
- 1995-09-08 CN CN95196308A patent/CN1046731C/zh not_active Expired - Fee Related
- 1995-09-08 ES ES95932693T patent/ES2157344T3/es not_active Expired - Lifetime
- 1995-09-08 EP EP95932693A patent/EP0783505B1/en not_active Expired - Lifetime
- 1995-09-08 MX MX9702307A patent/MX9702307A/es not_active IP Right Cessation
- 1995-09-08 DE DE69520282T patent/DE69520282T2/de not_active Expired - Lifetime
-
1997
- 1997-03-21 NO NO971342A patent/NO308108B1/no not_active IP Right Cessation
- 1997-03-24 FI FI971225A patent/FI112867B/fi active
-
2001
- 2001-06-06 GR GR20010400849T patent/GR3035996T3/el not_active IP Right Cessation
Cited By (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005502643A (ja) * | 2001-08-10 | 2005-01-27 | ノバルティス アクチエンゲゼルシャフト | 白血病処置のための単独またはsti571と組み合せたc−srcインヒビターの使用 |
| JP2009522284A (ja) * | 2005-12-29 | 2009-06-11 | アボット・ラボラトリーズ | タンパク質キナーゼ阻害薬 |
| JP2012505916A (ja) * | 2008-10-16 | 2012-03-08 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 融合環ヘテロアリールキナーゼ阻害剤 |
| JP2014193925A (ja) * | 2008-10-16 | 2014-10-09 | Regents Of The Univ Of California | 融合環ヘテロアリールキナーゼ阻害剤 |
| US9321772B2 (en) | 2011-09-02 | 2016-04-26 | The Regents Of The University Of California | Substituted pyrazolo[3,4-D]pyrimidines and uses thereof |
| US9895373B2 (en) | 2011-09-02 | 2018-02-20 | The Regents Of The University Of California | Substituted pyrazolo[3,4-D]pyrimidines and uses thereof |
| US10131668B2 (en) | 2012-09-26 | 2018-11-20 | The Regents Of The University Of California | Substituted imidazo[1,5-a]pYRAZINES for modulation of IRE1 |
| US10822340B2 (en) | 2012-09-26 | 2020-11-03 | The Regents Of The University Of California | Substituted imidazolopyrazine compounds and methods of using same |
| US11613544B2 (en) | 2012-09-26 | 2023-03-28 | The Regents Of The University Of California | Substituted imidazo[1,5-a]pyrazines for modulation of IRE1 |
| JP2022553376A (ja) * | 2019-10-25 | 2022-12-22 | アクセント・セラピューティクス・インコーポレイテッド | Mettl3モジュレーター |
Also Published As
| Publication number | Publication date |
|---|---|
| BR9509048A (pt) | 1998-01-06 |
| DE69520282T2 (de) | 2001-08-09 |
| HUT76785A (en) | 1997-11-28 |
| NO308108B1 (no) | 2000-07-24 |
| MX9702307A (es) | 1998-04-30 |
| WO1996010028A1 (en) | 1996-04-04 |
| EP0783505A1 (en) | 1997-07-16 |
| DE69520282D1 (de) | 2001-04-12 |
| CA2200210A1 (en) | 1996-04-04 |
| HU222181B1 (hu) | 2003-04-28 |
| ATE199553T1 (de) | 2001-03-15 |
| ES2157344T3 (es) | 2001-08-16 |
| CN1046731C (zh) | 1999-11-24 |
| GR3035996T3 (en) | 2001-09-28 |
| JP4145955B2 (ja) | 2008-09-03 |
| KR970706288A (ko) | 1997-11-03 |
| FI112867B (fi) | 2004-01-30 |
| AU3564395A (en) | 1996-04-19 |
| NO971342L (no) | 1997-03-21 |
| EP0783505B1 (en) | 2001-03-07 |
| CN1164234A (zh) | 1997-11-05 |
| FI971225L (fi) | 1997-05-14 |
| NO971342D0 (no) | 1997-03-21 |
| DK0783505T3 (da) | 2001-07-02 |
| FI971225A0 (fi) | 1997-03-24 |
| PT783505E (pt) | 2001-08-30 |
| US5869485A (en) | 1999-02-09 |
| AU694801B2 (en) | 1998-07-30 |
| NZ293249A (en) | 1999-04-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4145955B2 (ja) | ピロロ〔2,3−d〕ピリミジン及びその使用 | |
| JP3270830B2 (ja) | 化合物 | |
| JP5840492B2 (ja) | アリール−フェニル−スルホンアミド−フェニレン化合物とその使用 | |
| US5811459A (en) | Ortho substituted aromatic compounds useful as antagonists of the pain enhancing effects of E-type prostaglandins | |
| RU2270194C2 (ru) | Бензофеноны как ингибиторы il-1бета и tnf-альфа, фармацевтическая композиция и способ лечения | |
| JP2554824B2 (ja) | ピラゾロピリミジノン抗狭心性薬剤 | |
| DE69030206T2 (de) | Pyrazolopyridinverbindungen und Verfahren zu ihrer Herstellung | |
| CH690773A5 (de) | Pyrrolo(2,3-d)pyrimide und ihre Verwendung. | |
| EA005809B1 (ru) | Производные хиназолина в качестве ингибиторов киназы | |
| KR20120097508A (ko) | 벤조디아제핀 브로모도메인 억제제 | |
| JPH11501923A (ja) | 6−置換ピラゾロ〔3,4−d〕ピリミジン−4−オン並びにそれらを含有する組成物および使用方法 | |
| JP2003528095A (ja) | GSK3.β阻害剤としての2−アミノ−3−(アルキル)−ピリミドン誘導体 | |
| JP2001518906A (ja) | セロトニン様作用薬としてのインダゾールアミド化合物 | |
| KR19990071978A (ko) | 인단 다이머 화합물 및 그 약학적 용도 | |
| US5599813A (en) | Thiazolopyrimidine derivatives | |
| US4330546A (en) | 3-Aryl-3-aryloxypropylamines | |
| JP2001511798A (ja) | オキシド−スクアレンシクラーゼ抑制剤として有用な複素環化合物 | |
| JPH01268689A (ja) | 新規なベンゾイミダゾ〔1,2―c〕キナゾリン、その製造及び用途 | |
| JPH0377191B2 (ja) | ||
| CN103044460A (zh) | 3,5,7-三苯基-5H-噻唑并[3,2-a]嘧啶类衍生物及应用 | |
| JPS6344749B2 (ja) | ||
| WO2002024660A1 (en) | Imidazole derivatives or their salts | |
| JPS61267555A (ja) | キノリン誘導体及びそれを有効成分とする抗潰瘍剤 | |
| JP2002538134A (ja) | 療法に有用な1,2,3,4−テトラヒドロ−1−ナフタレンアミン化合物 | |
| JPH0892222A (ja) | N−フェニルアミド及び尿素誘導体 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060919 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20061219 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20080520 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20080619 |
|
| R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110627 Year of fee payment: 3 |
|
| LAPS | Cancellation because of no payment of annual fees |